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Abstract 
Background – Management of patients with suspected bacterial meningitis needs swift clinical 
decision making and early antibiotic initiation. However, the care of such patients in resource limited 
settings is challenging due to patients’ late presentation, limited diagnostic facilities and lack of 
evidence based treatment guidelines. 
Objective – To investigate the current strategies in the management of bacterial meningitis and to 
assess its discharge outcomes at teaching hospitals in Ethiopia 
Methods – Retrospective and prospective study designs were used. In the retrospective study, data 
was collected at four teaching hospitals in Ethiopia from patients who were treated as a case of 
bacterial meningitis from December 31, 2011 to April 30, 2015. The prospective study was conducted 
at Jimma University Hospital from March 1, 2013 to December 31, 2015. Descriptive analyses were 
done for most of baseline characteristics. Bivariate and multivariable analyses were also done to 
identify factors associated with unfavorable outcomes.  
Result – (i) Retrospective study: 425 patients of age 14 years and older were included in this study. 
Lumbar puncture was done for only 236 (55.5%) of cases. Only 96 (22.6%) of them had cerebrospinal 
fluid (CSF) abnormalities compatible with bacterial meningitis. A causative bacterium was identified 
in only 14 of the cases. Overall, 86 patients (20.2%) died while in the hospital. (ii) Prospective study: 
127 adults (≥18 years) participated in this study; 109 (85.8%) had their CSF analysed. However, only 
90 (70.9%) of them had findings suggestive of bacterial meningitis and causative bacteria were 
isolated in only 26 (20.5%). The over all in hospital mortality was 22.8% (29 deaths). Depressed level 
of consciousness, focal neurologic deficits and concomitant pneumonia on presentation were 
associated with increased in hospital death. 
Adjunctive dexamethasone treatment was used in 50.4% and 33.1% in retrospective and prospective 
studies, respectively, and was associated with unfavorable discharge outcome. 
Conclusion – Outcome in patients treated for bacterial meningitis in Ethiopia was found to be poor. 
Moreover, most of them did not receive proper diagnostic workup and alternative diagnoses were 
overlooked as a result. Adjunctive dexamethasone treatment was associated with unfavorable 
outcome at discharge. Thus, management of patients with suspected bacterial meningitis should be 
supported by laboratory tests and treatment should be tailored to evidences from the settings and 
current evidence-based recommendations.    
Key words – Bacterial meningitis, treatment, outcome, dexamethasone, Ethiopia, Africa 
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1. Introduction 
Bacterial meningitis (BM) is a very serious infection and a common cause of death and 
disability worldwide (1). Patients with BM are usually seriously ill and often present soon 
after symptom onset (2, 3). The classic clinical presentation of acute bacterial meningitis 
consists of fever, nuchal rigidity, and mental status change (1). However, in adults presenting 
with community-acquired acute bacterial meningitis, the sensitivity of the classic triads is low 
(4), but almost all of them present with at least two of the four symptoms of headache, fever, 
neck stiffness, and altered mental status (2, 3). 
Majority of cases of BM are caused by Neisseria (N.) meningitidis, Streptococcus (S.) 
pneumoniae, and Haemophilus (H.) influenzae (2, 5-7). Listeria (L.) monocytogenes is a 
common cause of bacterial meningitis in patients over 50 years of age or those who have 
deficiencies in cell-mediated immunity (8). 
The mortality and long term neurological sequelae associated with bacterial meningitis 
remain high even in the era of advanced antibiotic therapy and nursing care (2, 7, 9). In 
addition to factors associated with the host and pathogen (2, 9), the duration of disease and 
timing of antimicrobial treatment are important determinants of outcome (10). Thus, the 
management of acute bacterial meningitis needs swift clinical decision making and early 
commencement of antibiotics (11, 12). Evidence of brain infection and identification of 
causative organisms should be settled through cerebrospinal fluid (CSF) analysis (13).  
Despite having the highest burden of BM in the world (14), sub-Saharan Africa is least 
equipped to deal with this important public health problem (3).  Low health seeking 
behaviour, shortage of health workforce and underdeveloped health infrastructure (15) are 
important constrains to achieving these goals. Diagnostic facilities are limited and appropriate 
treatment modalities are difficult to access in primary hospitals in these settings (3).  
Evidenced based local guidelines for management of BM are also limited in the continent. As 
a result, management of patients with BM in most settings in Africa is based primarily on 
clinical grounds without confirmatory test for causative bacteria (16). For these reasons, BM 
presents an exceptional challenge to physicians working in resource-limited settings.  
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1.1. Bacterial meningitis: a global health issue 
Bacterial meningitis is one of the most common infectious diseases throughout the world 
today (17).  Globally, it is estimated that at least 1.2 million cases of bacterial meningitis 
occur every year, most of them in developing countries. The global reported cases of BM are 
attributable to invasive meningococcal disease due to its occurrence as an outbreak causing 
approximately 135,000 deaths per annum throughout the world (14, 18). It is at least ten 
times more common in developing countries than in the rest of the world (19). The mortality 
is also higher in such settings (7, 16, 20)  due to limited diagnostic facility and antibiotic 
options (3).  Additional factors such as advanced HIV infection (3, 21), malnutrition (22), and 
the emergence of antibiotic-resistant bacteria (23, 24), complicate the management of the 
infected patient. For these reasons, bacterial meningitis presents an exceptional challenge to 
physicians working in low income settings (3). 
About 80% of all cases of bacterial meningitis are caused by N. meningitidis, S. pneumoniae, 
and H. influenzae (3, 17, 25). However, the relative frequency of isolation of various bacterial 
species as a cause of meningitis varies with age, and among geographical regions (17). The 
major causes of community-acquired bacterial meningitis in adults in developed countries are 
S. pneumoniae and N. meningitidis whereas H. Influenzae is commonly seen in meningitis of 
the paediatric age group (2). L. monocytogenes is common cause of bacterial meningitis in 
patients over age 50 to 60 years or those who have deficiencies in cell-mediated immunity 
(8). 
Patients with bacterial meningitis are usually quite ill and often present soon after symptom 
onset. Depending on the study, the median duration of symptoms before admission is often 
only 24 hours (ranging from one hour to 14 days) (2). The classic clinical presentation of 
bacterial meningitis consists of fever, nuchal rigidity, and mental status change (1). However, 
in adults presenting with community-acquired bacterial meningitis, the sensitivity of the 
classic triads is low (4), but almost all present with at least two of the four symptoms of 
headache, fever, neck stiffness, and altered mental status (2, 3, 26).  
Despite advances in antibiotic therapy and nursing care, the mortality and long term 
neurological sequelae associated with bacterial meningitis remain high (9). Determinants of 
the pace of bacterial meningitis are related to both host and microbial virulence factors. The 
duration of disease (27), age (28) and immune status of the patient (29, 30), timing of 
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antibiotic initiation (26, 31), and type of microorganism (20, 32) are important factors in 
determining the outcome of bacterial meningitis. 
The strongest risk factors for an unfavorable outcome are those that are indicative of systemic 
compromise, a low level of consciousness, and infection with S. pneumonia (2). In general, 
the risk of death from bacterial meningitis increases with decreased level of consciousness on 
admission, onset of seizures within 24 h of admission, signs of increased intracranial pressure 
(ICP), age >50, the presence of comorbid conditions including shock and/or the need for 
mechanical ventilation, and delay in the initiation of treatment (1, 31). 
The overall mortality is highest for pneumococcal meningitis, with neurological morbidity 
affecting half of the survivors (33, 34). In-hospital mortality rates are 25% for S. pneumoniae, 
10% for N. meningitidis, and 21% for L. monocytogenes (1). Generally speaking, any form of 
bacterial meningitis that is untreated or treated very late in its course is almost uniformly fatal 
(31).  
Neurologic sequelae are common in survivors of bacterial meningitis. Moderate or severe 
sequelae occur in ~25% of survivors. Common sequelae include decreased intellectual 
function, memory impairment, seizures, hearing loss and dizziness, and gait disturbances 
(35). 
Morbidities and mortalities related to bacterial meningitis are said to increase in patients with 
HIV infection (36, 37). Even in the highly active antiretroviral therapy era, the risk of 
developing spontaneous bacterial meningitis (SBM) is 19 times higher among HIV-1-infected 
patients than among uninfected ones (36). SBM in HIV-1-infected patients carries a worse 
prognosis than in uninfected ones both in terms of lethality and sequelae (36, 37). Neurologic 
complications are three times as common and overall case fatality ratio is four times higher 
than non-HIV infected counter parts (36). 
Bacterial meningitis poses more challenge in sub-Saharan Africa than any part of the world. 
The continent has some of the highest rates of bacterial meningitis in the world (38). The 
burden of the problem is intensified by frequent outbreak of meningococcal meningitis in the 
region (39). Meningococcal meningitis is highest in the African meningitis belt that extends 
from Senegal in the west to Ethiopia in the east (Figure 1). The region consists of 26 
countries in sub-Saharan Africa (25). Over a span of 20 years from 1995 to 2014, total of 
900,000 cases of meningococcal meningitis were reported in these countries with 10% 
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fatalities and 10-20% documented neurological sequelae. The most recent large scale 
outbreak in the region occurred in 2009 in Niger and Nigeria with over 4,000 reported deaths 
(40).  
 
Figure 1-1 – The African Meningitis Belt 
Source: Control of epidemic meningococcal disease, WHO practical guidelines, 
1998, 2nd edition. (25) 
In addition to the burden of the problem, case management of bacterial meningitis is one of 
the great challenges of health care system in Africa and other low income countries (3). 
Diagnostic facilities are limited and appropriate treatment modalities are hardly accessible in 
these areas. Evidence based management guidelines are in short supply and hence treatment 
options are often derived from western data. As a result, the mortality and 
neuropsychological sequelae associated with the disease are highest in this part of the world 
(38).  
In conclusion, bacterial meningitis poses more problems in low income settings and in sub-
Saharan Africa in particular due to frequent occurrence of meningococcal meningitis, limited 
diagnostic facility and antibiotic option, and lack of evidence based guidelines. As a result 
management of patients with the problem in the setting is challenging.  
1.2. Bacterial meningitis in Ethiopia 
Ethiopia is one of the countries in the WHO African meningitis belt (25). Most documented 
data regarding epidemiology of bacterial meningitis in adults in Ethiopia are limited to 
surveillance and outbreak reports for meningococcal meningitis. Documented meningitis 
outbreak in Ethiopia dates back to 1901 with major outbreaks occurring almost every decade 
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in the 20
th
 century (41). The country recorded the largest outbreaks in 1980’s with reported 
mortality of over 1600 in 1989 alone (41, 42). However, the country is still having frequent 
small scale outbreaks throughout the country (41, 43-45).  
Information regarding sporadic bacterial meningitis in the country is scarce. A study in 
paediatric age group revealed that H. influenzae, S. pneumoniae and N. meningitidis account 
for about 90% of the cases (46). Findings in adults showed predominance of N. meningitidis 
and S. pneumoniae. These studies also showed that the isolation rate of causative bacteria was 
between 5 and 10% of those suspected with bacterial meningitis (44, 47). A significant 
proportion of those who presented to the hospital were treated with one or more antibiotics 
for the same complaint before admission (48). 
The morbidities and mortalities related to meningitis in Ethiopia are also immense. 
Epidemiological studies in Ethiopia found the fatality rates for meningococcal meningitis and 
meningococcemia to be 16% and 85% respectively (42). In another study, a quarter of 
children treated for meningitis were found to have hearing loss at discharge (49). However, 
the overall epidemiology of the disease remains poorly understood due to lack of data from 
well-designed studies. 
As a result, the overall incidences and spectrum of complications, and prognostic factors in 
adults with bacterial meningitis in Ethiopia is not well known. In addition to this, poor health 
service system has made care of patients with meningitis to be extremely challenging. 
Diagnosis is based mainly on clinical grounds and treatment is entirely pragmatic. 
Patients’ late presentation due to multiple factors, scarce laboratory facilities, limited 
antibiotic options, underdeveloped infrastructure to access health service, scarce number of 
health workforce, and most importantly, lack of clear cut national strategy for care of patients 
with meningitis are further setback. Moreover, the sensitivity and specificity of the signs and 
symptoms of bacterial meningitis has never been validated in the country and evidences 
regarding antibiotic susceptibility pattern is extremely scarce.   
The aim of this study was thus to identify specific critical points that need be addressed to 
improve medical workup and treatment of patients with bacterial meningitis in this country. 
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2. Objectives 
As it has been highlighted earlier, data regarding the burden of the problem and clinical 
evidences for development of treatment guidelines for bacterial meningitis in Ethiopia is 
limited. Addressing these important gaps is key step in the direction of improving case 
management of patients with the disease. The main purpose of this project was to assess the 
current diagnostic and treatment strategies in the management of adult patients with bacterial 
meningitis in Ethiopia. The goal is to create a scientific basis for developing guidelines for 
the diagnosis and treatment of meningitis in rural parts of Ethiopia where resources are 
limited. 
2.1. Objectives of the study 
General objective 
To assess treatment strategies and outcome in adult patients with suspected bacterial 
meningitis admitted to teaching hospitals in Ethiopia. 
Specific objectives 
1. To evaluate strategies used to diagnose and treat bacterial meningitis in Ethiopia 
2. To identify the common causes of bacterial meningitis in the setting 
3. To assess treatment outcome at discharge 
4. To investigate factors associated with unfavorable discharge outcomes 
2.2. Major research questions 
1. What are the major clinical presentations of patients with suspected BM? 
2. How was the diagnosis established? (Clinical only? CSF analysis? 
Microbiologically confirmed?) 
3. What are the common bacterial etiologies? 
4. How were the patients treated? (Antibiotic choice? any adjunctive treatment? were 
the patients treated for other differential diagnoses?) 
5. What is the outcome at leaving hospital (death or neurologic sequelae)? 
6. What are the major factors associated with unfavorable outcomes? 
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3. Methods 
This research project employed two types of research design: retrospective data collection 
and prospective follow-up of patients admitted with presumptive diagnosis of bacterial 
meningitis. The methods employed by each design will be detailed as follows. 
3.1. Retrospective study 
3.1.1. Study setting 
This study was conducted at four teaching hospitals in Ethiopia – Jimma University 
Specialized Hospital, Hawassa University Referral Teaching Hospital, University of Gondar 
Hospital and Arba Minch Hospital. The first three are full-fledged university hospital serving 
as referral hospitals. Arba Minch hospital is a general hospital affiliated with Arba Minch 
University’s medical school. All of these hospitals are located in the meningitis belt of Africa 
– Gondar in the northwest, Jimma in the southwest and Arba Minch and Hawassa in the south 
(Figure 2). Moreover, all serve the regions which have reported outbreaks of meningococcal 
meningitis in the last ten years (43-45). The overall catchment population for the four 
hospitals is nearly 25 million – over a quarter of the Ethiopian population.  
The diagnosis of bacterial meningitis in the country is based mainly on clinical 
manifestations and microscopic findings of the CSF. Patients suspected with meningitis 
undergo lumbar puncture procedure unless there are contraindications. As routine CT 
scanning for such patients in Ethiopia is not available, contraindications for the procedure are 
based on clinical judgement only. Accordingly, those with focal neurologic deficits at 
presentation, papilledema, and significantly depressed mentation (GCS <5/15) do not 
undergo the procedure.  
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Figure 3-1– Location of Teaching Hospitals included in the study 
3.1.2. Study participants 
Patients included in this study were those of age 14 years and older treated with a 
presumptive diagnosis of bacterial meningitis during the period of January 1, 2011 to April 
30, 2015. Only patients who had complete medical records regarding issues related to 
diagnosis, treatment and outcome of BM were included in the study.  Patients whose 
antibiotic treatment was discontinued before ward admission because of confirmed 
alternative diagnosis were excluded.  
Definition of the cases – Cases treated as bacterial meningitis were categorized according to 
their clinical presentation and CSF findings based on the 2003 World Health Organization 
case definition used in WHO-recommended surveillance standards for surveillance of 
selected vaccine-preventable diseases (50). These categories are: 
1. Suspected unproven cases of bacterial meningitis – Cases with sudden onset (≤7days) of 
fever (axillary temperature of ≥38.0°C) PLUS any of: neck stiffness and altered 
consciousness PLUS no other alternative diagnosis PLUS no or incomplete CSF analysis.   
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2. Possible bacterial meningitis – A case with clinical signs as described for “suspected 
unproven BM” PLUS CSF examination showing at least one of the following three – (1) 
Turbid appearance (2) Pleocytosis (>100 white cells/mm3) (3) Pleocytosis (10-100 white 
cells/mm3) AND either an elevated protein (>100 mg/dl) or decreased CSF to serum 
glucose ratio (< 40%).  
3. Confirmed (proven) bacterial meningitis – Cases with detected microorganisms from CSF 
specimen by one or more of the following methods: culture, gram stain microscopy or 
latex agglutination test.  
4. Non-cases (diagnosis of bacterial meningitis doubtful or less likely) – Cases not fulfilling 
any of the above criteria and/or those with evidences suggesting other diagnoses.   
3.1.3. Data collection procedures   
Patients treated as cases of BM were identified using the data from inpatient registration 
books of medical wards at each hospital. Using six digit medical registration numbers, 
patients’ records were retrieved from the archives for data collection. The data was collected 
by a standardized case report form (see Annex – 1). The information gathered included 
socio-demographic profiles, presenting clinical signs and symptoms, CSF findings and other 
laboratory results, the applied treatment regimens, clinical course in the hospital, and 
discharge conditions (death and neurologic sequelae).  
The data was collected by general practitioners and medical residents after they were trained 
for one day about data collection procedures. 
The data was between February 1, 2015 and May 31, 2015. 
3.1.4. Outcome measurements   
The status of the patient at leaving the hospital (death, regular discharge or self-discharge) 
was retrieved from treating physician’s document. Any reported death along its possible 
immediate causes was reviewed from death summary document. The discharge note was 
reviewed to find out if there were any neurologic sequelae at leaving hospital. As there was 
no routine assessment of GOS at the hospitals, the data was obtained from discharge or death 
summary attached in patient’s medical chart. The scales were elaborated based on physician’s 
record as: 1=if death was documented; 2=if patient was in ‘coma’ or ‘unresponsive’ at 
leaving hospital; 3=if document included any of ‘hemiparesis’, ‘paraparesis’, or ‘major 
disability’; 4=if document included ‘facial palsy ‘or if any milder neurologic deficits were 
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reported – such as ‘decreased hearing capacity’; 5=if document included ‘full recovery’ or 
‘improved’.  The scores were dichotomized into favorable (5) and unfavourable (1 to 4) 
outcomes. 
3.2. Prospective study  
3.2.1. Study setting 
The prospective study was conducted at Jimma University Specialized Hospital (JUSH). It is 
the only teaching hospital in southwest Ethiopia with catchment population of over 15 
million.  It is located in Jimma town, 352 km southwest of the capital Addis Ababa. The town 
is situated in the meningitis belt of Africa. 
There was no bacteriology unit at Jimma University hospital before. The service was 
established at the hospital as part of this project and is functional since 26 October, 2013. 
Microbiologic analyses of CSF specimen using microscopy of gram stain specimen, latex 
agglutination test (LAT) and culture with antibiotic susceptibility tests are part of routine care 
for BM at the hospital now. Dr Andreas Wieser from Max von Pettenkofer-Institute for 
Hygiene and Clinical Microbiology of Ludwig Maximilians-University, Munich led the 
designing and establishment of the unit. He also served as the lead microbiologist of the unit 
during the first six months and also gave on service training for local staffs. 
 
  
Figure 3-2 – Bacteriology Unit of Jimma University Specialized Hospital 
 (Established October 2013) 
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3.2.2. Study participants 
Participants in this group were those with suspected bacterial meningitis and 18 years or older 
at the time of hospital admission. In general, participants included in this group fell into four 
categories based on likelihood of bacterial meningitis (inclusion criteria used). 
I. Bacterial meningitis with proven/confirmed etiology 
Patients with clinically suspected BM supported by confirmed etiology by one or 
more of these methods: culture, gram stain microscopy or latex agglutination test.  
II. Bacterial meningitis with unidentified (Unknown) etiology  
Patients with at least three of the following four CSF findings: (i) Turbid CSF, (ii) 
≥1000 white cells/µL, (iii) Protein >100mg/dl and (iv) CSF to serum glucose ratio 
of <0.4 WITHOUT detection of causative bacteria from CSF. 
III. Possible bacterial meningitis 
a. Abnormal CSF but not fulfilling the above criteria (WBC ≥100 but <1000 or 
WBC>10 PLUS glucose ratio<0.4 PLUS protein>100).  
b. Where LP was not possible due to contraindications or technical problems, 
patients with all of these symptoms (fever> 39
0
C, nuchal rigidity, mental 
status change) lasting 7 days or less since on set PLUS negative blood film for 
Plasmodium falciparum where included.  
Patients in both ‘a’ and ‘b’ were included only if diagnosis other than bacterial 
meningitis was found to be less likely on clinical examination and laboratory. 
IV. Bacterial meningitis less likely – they were patients empirically treated by 
treating doctor as BM with full course of antibiotics though the evidence 
supporting its diagnosis was lacking. These cases were separated into two 
subgroups: 
a. Alternative (other differential) diagnosis possible – they were cases with the 
following characteristics: (i) clear evidences of brain insult (body weakness, 
seizure, impairments of consciousness, nuchal rigidity) (ii) clinical 
presentations atypical for BM, e.g., long duration of symptoms (>1 week); 
absence of triads of BM; or symptoms suggestive of  other diseases (iii) CSF 
findings not compatible with bacterial meningitis described in ‘I’ to ‘III’ 
above or suggestive of or confirmatory of alternative diagnosis.   
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b. Non-cases (doubtful cases) – cases not fulfilling any of the above criteria: (i) 
no clear evidence of brain affection AND (ii) normal CSF findings.  
Exclusion: - Those with proven chronic meningitis of any cause 
 Those with posttraumatic meningitis 
 Patients with prior residual neurologic deficit lasting less than 3 months 
 Symptomatic chronic psychiatric disorders  
All patients who fulfilled the inclusion criteria and willing to participate on the study were 
recruited consecutively. 
3.2.3. Data collection procedures  
The data study was conducted from March 1, 2013 to December 31, 2015 (34 months). The 
data was collected by using pretested structured questionnaire specifically prepared for this 
study (see Annex – 2).  Patients, the guardian if patient was unconscious, were asked for 
consent before data collection. Figure 3.3 shows flow chart for evaluation of patients from 
admission to discharge.  
Admission assessment – The initial interview was done by the treating physician to obtain 
information regarding demographic profiles (age, gender, and residence), duration of illness 
and symptoms at presentation. Physical examination was done at presentation by the same 
person to assess general condition, vital signs, mental status, signs of meningitis (nuchal 
rigidity, Kerning’s sign, Brudzinski's sign), and presence of neurologic deficit.  
Collection and processing of CSF specimen – Lumbar puncture, in the absence of 
contraindication, was done under possible aseptic condition for all patients with suspected 
BM to collect CSF specimen. This was done as soon as it was possible (before antibiotics 
administration). However, if the LP was not possible within an hour of presentation or 
consideration of diagnosis of BM, patient was given first dose of antibiotics and CSF 
collection was done within 24 hours of this. About 2-3 ml of CSF specimen was collected in 
two separate sterile tubes each.  In case the tap was traumatic, the specimen was collected 
serially until the fluid became clear. The tubes were labelled as ‘1’ and ‘2’ based on their 
collection. The specimen was then sent to microbiology unit within 30 minutes of collection 
with special request form that contains demographic data, brief clinical description and 
whether patient has taken any prior antibiotics or not. 
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ADMISSION ASSESSMENT   
Bacterial meningitis suspected cases 
(Fever, Headache, change of sensorium not exceeding 7 days) 
Thorough History taking and physical 
examination at admission 
Laboratory Investigations 
Other laboratory evaluations  
 Complete blood count 
 Erythrocyte sedimentation 
 Random plasma glucose 
 Blood film 
 HIV test 
 Other tests as indicated 
Lumbar puncture and 
CSF analysis 
Biochemical and 
Microscopic analysis, 
LAT 
Culture and sensitivity 
for common bacteria 
causing BM 
Daily symptom 
assessment  
Neuro-sign follow-up 
GOS 
IN PATIENT FOLLOW-UP 
Vital sign follow-up every 
four hour for the first two days 
and daily after that 
DISCHARGE ASSESSMENT 
Routine clinical 
evaluation at discharge  
MMSE Mortality report 
AFB for TBM 
Indian ink and SDA culture for fungal 
causes in HIV patients 
Figure 3-3 Flow chart for evaluation of patients treated as bacterial at Jimma University Specialized hospital 
AFB – Acid-fast bacilli, CSF – cerebrospinal fluid, GOS – Glasgoc outcome scale, LAT – latex agglutination test, MMSE – 
Minimental state examination, SDA – Sabouraud's dextrose agar, TBM – Tuberculous meningitis 
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Samples were processed within ½ an hour to 1 hour of collection. Macroscopic appearance of 
CSF was observed and documented as crystal clear, turbid or bloody/traumatic by both the 
collecting physician and the laboratory personnel independently. Biochemical, cytological 
and microbiologic analysis of the specimen was done and interpreted according to guideline 
highlighted in Annex – 3.  
Other laboratory tests and work-up – Plasma glucose was determined for all patients on 
presentation. However, only glucose level determined two hours before or after CSF 
collection was used for assessment of CSF to serum ratio. Complete blood count, blood film 
(BF) for hemoparasite and erythrocyte sedimentation rates (ESR) were done on presentation 
or a day after admission. Patients who were suspected to have chest infection were sent for 
chest radiography as soon as it was possible. 
Rapid test for HIV was done within three days of admission for all patients and as soon as 
possible in patients suspected to have the infection. The standard confirmatory test was done 
for those with rapid test positive; tie-breaker test was done if there was discrepancy between 
the two (all done as part of routine practice). HIV test was not needed in those with known 
diagnosis. CD4 count and routine evaluation for status of HIV infection (WHO staging) were 
done before discharge when possible. Otherwise, patients with stable conditions were 
discharged and given short appoint for HIV treatment (as part of routine care).  
Inpatient follow-up – The course of the disease, complications, and outcome in the hospital 
were assessed as described below: (see Annex – 2) 
 All treatment regimen given were documented from order sheet located in patient’s 
chart– type, dose and route of antibiotics; adjunctive treatment (e.g., dexamethasone); 
treatment for additional or alternative diagnosis  
 Patients were interviewed daily for symptom improvement or occurrence of new 
symptoms. 
 Vital signs were assessed every 4 hourly for the first 48 hours and daily after that. 
Patients who did not show improvement in the first two days were also closely 
followed until improvement, death or leaving hospital. 
 Daily follow-up with neurosign chart that included the following variables: Glasgow 
coma scale (GCS), seizure, headache, and nuchal rigidity was done during the course 
in hospital. 
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 Death occurrences were documented along with the date and possible immediate 
causes using separate format  
 Discharge outcome was done using Glasgow outcome scale (GOS) (see below) 
 Patients were also assessed at discharge for gross neurologic deficits (visual problem, 
hearing loss, body weakness) and minimental state examination. 
Data collectors 
All clinical assessments were done by medical residents directly involved in the care of 
patients with bacterial meningitis. Microbiologic analysis of the CSF specimen was done by 
laboratory professionals who received adequate (>3 months) onsite training by microbiologist 
from Ludwig-Maximilians University of Munich, Germany (Dr. med. Andreas Wieser). A 
research nurse was recruited specifically for this project to serve as a link between principal 
investigator, data collector physicians and laboratory personnel. He was responsible for 
taking collected CSF specimen to the laboratory, supervise daily in patient   follow-up, 
collecting laboratory results and compiling of individual patient data.  
The project was presented to all clinical staffs working in department of internal medicine 
before the commencement of data collection (February 2013). Detail data collection 
procedure and specimen handling was presented to all data collectors (all medical residents) 
after that. This was repeated at different times based on the gaps identified during data 
collection. All newly joining residents were also trained as required.   
3.2.4. Outcome measurements  
The primary outcome measurements were GOS and mortality at discharge. Neurologic 
deficits at discharge, length of hospital stay, and mini-mental state examination (MMSE) 
were the other outcome measurements. 
Glasgow outcome scale (GOS) is a five-point scale described as—death=1, persistent 
vegetative state=2, severe disability=3, moderate disability=4, and good recovery=5 (51). The 
scores were dichotomized into favorable (5) and unfavourable (1 to 4) outcomes. (See 
Annex – 2)  
Mini-mental state examination (MMSE) – a 30 point score (Folstein test (52)) cognitive 
function assessment was done at discharge. This was used in prospective study only. Scores 
of 24-30 were categorized as normal. (Annex – 2) 
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Note: - MMSE was done only in patients who were conscious and were literate enough to do 
it. 
3.3. Data quality control 
The following data quality control measures were taken in both types of the studies: 
 All clinical evaluations were done by clinician who had experience in care of the case. 
 Data collectors were selected based on their interests only 
 Data collectors were trained and data collection was supervised 
 The questionnaire was pretested before data collection 
 The data was double entered to minimize errors 
3.4. Data processing, analysis and interpretation  
The collected data were checked for completeness and consistency and then entered to 
EpiData version 3.1. The data were later transferred to SPSS® (IBM Corporation) version 20 
for analysis. Descriptive statistical analysis was used to present sociodemographic variables, 
clinical and laboratory data of the patients. Trend change in disease pattern was analysed in 
relation to seasonal change and average annual rain fall and presented in graphs. 
 Chi-square test where applicable was done to test binary association between dependent and 
independent variables. T-test was done for continuous variables. Bivariable analysis was 
done to identify association between dependent and independent variables. All independent 
variables with p<0.25 in bivariate analysis were entered for multivariable analysis. Forward 
logistic regression analysis was done to identify the best fit model. Independent predictors 
were analysed for three outcome variables – death, Glasgow outcome scale and neurologic 
sequelae at leaving hospital. P-value of <0.05 was used as level of statistical significance. 
3.5. Operational definitions  
Anemia – defined as hemoglobin concentration of <12 g/dl in women and <13 g/dl for men. 
Hemoglobin level <8 g/dl was considered as severe anemia.  
Antimeningeal dose of antibiotics – refers to high dose intravenous antibiotics (ceftriaxone 
2gm every 12 hours, ampicillin 3gm every 6 hours, benzyl penicillin 4 million units every 4 
hours). 
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Level of consciousness – was assessed using Glasgow Coma Scale (GCS) which has a score 
of 3 to 15. Full consciousness refers to score of 15; a score of 9-14 was considered as 
impaired consciousness and patients with a score of 8 or less were classified as comatose. 
Neurologic deficit refers to (1) unilateral extremity weakness [monoparesis or hemiparesis] 
(2) unilateral loss of sensation (3) localized cranial nerve palsies (III, IV and VII). 
3.6. Ethical considerations  
The study was approved by College of Health Science Ethical Review Board at Jimma 
University (Reference letters RPGC/24/2013 and RPGC/4026/2015). Official letter was then 
written by the review board to each respective hospital to facilitate access to the archives. 
Written informed consent was obtained from patients or close family member if the patient 
was uncommunicative (for prospective study). Culture findings and antibiotic susceptibility 
test results were communicated to the treating physicians as soon as the results were known. 
Physicians at the hospitals were informed about the findings to make use of them in patient 
care. Data was collected using medical registration number and patients initials only. 
Confidentiality of the data was ensured through anonymity. 
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4. Results 
4.1. Retrospective study  
Background characteristics – A total of 425 patients treated for suspected bacterial 
meningitis at four teaching hospitals in Ethiopia were included in this study; 224 (52.7%) of 
them were male. The mean age at presentation was 32 years (SD = 15.7) with a range of 14 to 
85 years; 356 (83.8%) were younger than 50 (Table 4.1). 
Table 4-1 – Background characteristics of patients treated as bacterial meningitis at teaching 
hospitals in Ethiopia, 2011 – 2015. 
Characteristics  Number  Percent  
Gender   
Male  224 52.7 
Female  201 47.3 
Age at presentation   
< 50 years  356 83.8 
≥ 50 years 69 16.2 
Duration of illness before presentation   
0-2 days 127 29.9 
3-7 days 234 55.1 
>7 days  64 15.1 
Presenting symptoms and signs   
Fever  384 90.4 
Headache  359 84.5 
Nuchal rigidity  238 56.0 
Vomiting  243 57.2 
Loss of consciousness   213 50.1 
Seizure  98 23.1 
Photophobia  42 9.9 
Focal neurologic deficit 33 7.8 
Prior antibiotic treatment 104 24.5 
Hospital   
Arba Minch 126 29.6 
Gondar 92 21.6 
Hawassa 85 20.0 
Jimma 122 28.2 
Risk factors/comorbidities identified   
HIV 23 5.4 
Pregnancy  14 3.3 
Diabetes mellitus 8 1.9 
Current alcohol user 7 1.6 
Current smoker  3 0.7 
Acute otitis media 2 0.5 
Chronic otitis media 1 0.2 
Head injury and CSF leak 2 0.4 
24 
 
Presenting clinical symptoms: Fever, headache and neck stiffness were the most common 
presenting symptoms reported in 384 (90.4%), 359 (84.5%) and 238 (56 %) of cases, 
respectively. At presentation to the emergency unit, 213 (50.1% had impaired consciousness 
(GCS<15) and 7.8% had focal neurologic deficit. 
On average, the duration of illness before presentation was 5.1 days (SD=4.3). About 85% of 
patients presented within a week of onset of symptoms. However, only 79 (18.6%) patients 
presented within a day after symptoms had begun. Nearly quarter of the patients (104) were 
treated in the community with antibiotics for similar complaints. HIV infection and diabetes 
mellitus were the most common comorbidities identified and were reported in 5.4% and 1.9% 
of cases respectively (Table 4.1).  However, the diagnosis of diabetes was self-report and 
17.9% of patients did not receive HIV test. Thus, the report of these comorbidities may be an 
under estimate of the real prevalence. 
Table 4-2 – Diagnostic and ancillary laboratory investigations done in patients treated as 
bacterial meningitis at teaching hospitals in Ethiopia, 2011 – 2015.   
Type of laboratory tests  Number   Percent  
Lumbar puncture done  236 55.5 
Reasons documented for not doing LP (N=189)   
Contraindications 49 25.9 
Technical problem (failed attempt) 9 4.8 
No LP set 2 1 
Not known  126 66.7 
CSF analysis (N=236)   
Glucose  165 69.9 
Protein  137 58.1 
Cell count  180 76.3 
Gram stain (microscopy) 220 93.2 
Culture  61 25.8 
AFB test 208 88.1 
Indian ink for Cryptococcus 80 33.9 
Other supportive tests (N=425)   
Complete blood count  335 78.8 
Erythrocyte sedimentation rate  156 36.7 
Blood glucose 246 57.9 
HIV test  349 82.1 
Blood film for hemoparasite 397 93.4 
LP – lumbar puncture, AFB – acid fast bacilli 
Diagnostic strategies – Only 236 (55.5%) of patients had a lumbar puncture done to collect 
CSF specimen. Among them, 220 (93.2%) had microscopic examination of Gram-stain 
specimen for causative bacteria and 180 (76.3%) had leukocyte count done. However, only 
58.1% had analysis for both protein and glucose. Culture and antibiotic sensitivity tests were 
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done in only 61(25.8%) cases (Table 4.2). A pathogen was identified in only 14 cases (6%) 
of those who had their CSF collected. Blood culture was not done in any of the patients.  
Findings from CSF analysis showed that only less than half of the patients had one or more of 
the following abnormalities considered as  compatible with bacterial meningitis – CSF/serum 
glucose ratio < 0.4 or WBC ≥ 100cells/mm
3
 or protein >100mg/dl (Table 4.3). Causative 
bacteria were detected by microscopic examination of CSF specimen in only 13 cases; seven 
of them were reported as gram-negative intracellular diplococcus (Neisseria meningitidis) 
whereas six were reported as extracellular gram-positive diplococcus (Streptococcus 
pneumoniae). Only one of these cases was positive on culture.  In another case with negative 
gram-stain finding, culture was found to be positive for Streptococcus pnuemoniae.  One 
patient who was also positive for HIV had confirmed cryptococcal meningitis. 
In other supportive tests, 38% had peripheral leucocytosis and 4% were severely anaemic. 
Twenty-eight patients had positive blood film for plasmodium species (Table 4.3). 
Table 4-3 – Supportive laboratory findings for diagnosis of bacterial meningitis in patients 
treated as bacterial meningitis at teaching hospitals in Ethiopia, 2011 – 2015.   
Laboratory findings Number   Percent  
CSF analysis   
Turbid/cloudy CSF (of 235 cases) 57 24.3 
CSF glucose (of 111 tested)   
CSF/serum ratio <0.4 47 42.3 
White cell count (of 180 tested)   
>10 cells/mm
3
 116 64.4 
>100 cells/mm
3
 81 45.0 
>1000 cells/mm
3
 34 18.9 
Protein (of 140 tested)   
>50 mg/dl 83 59.3 
>100 mg/dl 59 42.1 
Organism detected by microscopic 
examination of CSF (of 220 tested) 
13 5.9 
Positive culture (of 61 tested) 2 3.3 
Complete blood count (total = 335)   
Leukopenia (<4000/μl) 33 9.9 
Leucocytosis (>11,000/μl) 127 37.9 
Anemia 105 31.3 
Severe anemia 13 3.9 
Blood film Positive for malaria (T=397) 28 7.1 
Overall, the diagnosis of bacterial meningitis was microbiologically confirmed in only 14 
(3.3%) cases whereas additional 82 (19.3%) cases had CSF abnormalities compatible with 
bacterial meningitis (possible bacterial meningitis). Another, 196 (46.1%) patients fulfilled 
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the World Health Organization (WHO) criteria for clinical suspected unproven cases of 
bacterial meningitis. The rest, 133 (31.3%) did not fulfil both clinical and laboratory criteria 
for definition of bacterial meningitis (non-cases). On further analysis, 82 (41.8%) of 
suspected unproven cases and 58 (43.6%) of the non-cases had at least partial analysis of 
their CSF. None of these groups had findings that supported the diagnosis of bacterial 
meningitis but they continued to receive antibiotics as so. 
In general, of the 236 patients who had their CSF analysed, only 96 (40.7%) had findings 
compatible with diagnosis of bacterial meningitis. This means, among all patients treated as 
bacterial meningitis; only 22.6% (96/425) were supported by CSF findings (Figure 4.1). 
 
Figure 4-1– Classification of the cases based on WHO case definition for bacterial 
meningitis in patients treated as bacterial meningitis (BM) at teaching hospitals 
in Ethiopia, 2011 – 2015.   
Treatment strategies  
Antibiotic choice: All of the patients were given antimeningeal dose of intravenous 
antibiotics until death, hospital discharge or for at least 10 days in case patient stayed in 
hospital for other reasons. Except for one patient, all of them took ceftriaxone either as a 
single agent or in combination with other antibiotics; 75 (17.6%) were given vancomycin and 
23 (5.4%) took ampicillin as additional treatment. Intravenous metronidazole was given to 44 
(10.4%) patients for suspected aspiration pneumonia. 
We have also tried to assess if selection of antibiotics used was based on clinical profiles of 
the patients. This analysis showed that there was no difference in vancomycin use among age 
Suspected 
unproven cases, 
46.1% 
Possible BM, 
19.3% 
Confirmed 
cases, 3.3% 
Non-cases, 
31.3% 
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groups and clinical conditions of the patients. On the other hand, it was found that ampicillin 
was administered more often in pregnant woman, 85.7% vs 5.1% in non-pregnant (P<0.001) 
and those older than 50 years of age (26.1% vs 1.4% in younger patients (P<0.001)).  
Antibiotic choices and duration of therapy for BM did not significantly vary with clinical 
scenario of the patient and CSF findings. However, variations were observed between 
hospitals and even within each hospital.  
Concomitant treatment for additional etiology: As stated above, etiologic diagnosis was not 
possible from CSF for most of the patients. Hence, physicians took pragmatic approach of 
treating these patients for other differential diagnoses. Accordingly, 149 (35.1%) patients 
were treated for one or more of these additional diagnoses (Tuberculous meningitis, viral 
meningitis, cryptococcal meningitis and severe malaria). Eighty-seven (20.5%) were given 
antimalarial treatment, however, only 28 (32.2%) of them were confirmed by blood film and 
only 19 were having Plasmodium falciparum. Anti-tuberculous treatment was given 
empirically for 53 (12.5%) though they were not confirmed by laboratory.  Twenty-two 
patients were also treated with high dose oral acyclovir when viral meningitis seemed also 
possible on clinical ground. All of these patients treated for alternative/additional diagnosis 
were also given full antibiotic regimen for BM. Figure 4.2 summarizes diagnostic and 
therapeutic flow chart employed for overall management of the cases.  
As the cases treated for TB meningitis and viral meningitis were not confirmed by laboratory, 
we tried to assess if these patients were clinically different from the other groups. In this 
regard, patients treated as TB meningitis were those who had longer duration of illness before 
presentation, 8.8 versus 4.7 days (P<0.001); had prior antibiotic treatment before hospital 
presentation, 18.3% versus 10.6% (p=0.04) and had focal neurologic deficit, 27.3% versus 
11.3% (p=0.008). However, patients treated as viral meningitis had similar clinical profile as 
others except that they had higher rate of seizure, 10.2% versus 3.7% (p=0.01) and loss of 
consciousness, 8.1% versus 2.8% (p=0.024).  
Adjunctive dexamethasone treatment: Adjuvant dexamethasone was given to 214 (50.4%) of 
patients. It was used in 85.7% of proven, 62.2% of possible and 42.9% of suspected BM. It 
was also used in 57.7% of patients who did not have CSF analysis.  Moreover, 52.3% patients 
treated for additional etiologies were also given this adjuvant therapy. 
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Patients treated for suspected 
Bacterial meningitis 
N = 425 
CSF analyzed 
 N=236 
CSF not analyzed 
N=189 
Proven 
meningitis 
N= 14 
Possible 
meningitis 
N=82 
Not compatible
‡
 with 
BM 
N= 140 
No additional 
diagnosis 
N=56 
Additional
† 
diagnosis 
N =50 
Additional
† 
diagnosis 
N= 69 
5 Severe malaria 
19 TBM 
5 Viral meningitis 
(4 of them were 
treated for two or 
more of these) 
Additional
† 
diagnosis 
N=26 
No additional 
diagnosis 
N=90 
No additional 
diagnosis 
N=120 
28 Severe malaria 
13TBM 
14 Viral meningitis 
2 Cryptococcal meningitis 
(7 of them were treated 
for two or more of these) 
52 Severe malaria 
18 TBM 
3 Viral meningitis 
1 Cryptococcal meningitis 
(5 of them were treated for 
two or more of these) 
‡ CSF was only partially analysed for 42.7% of the cases; not enough to completely rule out bacterial meningitis 
† None of the TBM (Tuberculous meningitis) and viral meningitis cases were confirmed microbiologically, only 1 of the cryptococcal meningitis 
cases and 28 of malaria cases were confirmed. Treatment was thus mostly empiric.  
All 425 patients took full regimen of antibiotics for bacterial meningitis (BM). 
Patients treated for additional 
diagnosis
† 
(N=4) 
2 TBM 
1 Sever malaria 
1 Both TB & malaria 
 
Overall, 149 were treated for 
additional
†
 diagnoses 
87 Severe malaria 
53 TBM 
22 Viral meningitis 
3 Cryptococcal meningitis 
Some patients took treatment 
for multiple of these conditions. 
 
Figure 4-2– Classification of cases treated as bacterial meningitis based on diagnosis and treatment approach used at teaching hospitals in Ethiopia, 
2011 – 2015. 
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Seasonality of the disease occurrence 
Trend change in number cases was analysed in relation to the amount of average annual rainfall 
pattern. There was no smooth variation of number of cases in relation to the amount of rainfall. 
However, the peak number of cases between November and January correlates well with the 
lowest annual rainfall. On more specific analysis for probable and confirmed cases of bacterial 
meningitis, the peak was in dry month of January whereas the nadir was registered in August, the 
month with highest rainfall (Figure 4.3). 
 
*Data extracted from National Metrology Agency (http://www.ethiomet.gov.et/)  
Figure 4-3 – Seasonal variability of number of cases treated as bacterial meningitis with rainfall 
pattern 
In terms of yearly change, 321 (75.5%) of patients were treated in the year 2013 and 2014. Whether the 
steady increment from 2011 and 2012 was due to change in pattern or lost documents in the earlier year is 
not clearly know though the latter is most likely explanation. The seasonal variation in each year also 
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lacks clear pattern but, the number of reported cases were found to be highest between December and 
February (the driest months of the year) each year except for 2014 (Figure 4.4). 
 
Figure 4-4 – Number of cases treated as bacterial meningitis by season and year at teaching 
hospitals in Ethiopia 
Discharge outcome – 156 (36.7%) had unfavorable outcome (GOS = 1-4) at leaving hospital. 
The overall in hospital mortality rate was 20.2% (86 deaths). There were differences in mortality 
rates based on case definition of bacterial meningitis; 26.0% in suspected unproven cases, 20.7% 
in possible bacterial meningitis, 28.6% in confirmed cases and 10.5% in non-cases (P<0.0001).  
The median time from hospital admission to death was 3 days; 55.8% happened in the first 4 
days after admission.  
Of those who left the hospital alive (339), 277 (81.7%) were discharged and 57 (16.8%) left 
against medical advice (LAMA). Among surviving patients, 70 (20.6%) had unfavourable GOS 
(2 to 4); 38 (11.2%) had documented neurologic sequelae.  
The average length of hospital stay (LOS) for discharged patients was 11.0 days (SD=6.6). 
Those who left against medical advice had a LOS of 6.1 days (SD=3.7) and 52.6% of them left 
in the first 4 days of admission (Table 4.4).   
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Table 4-4 – Outcome at leaving hospital in patients treated as bacterial meningitis at teaching 
hospitals in Ethiopia, 2011 – 2015. 
Characteristics  Number  Percent  
Status at leaving hospital (N=425), n (%)   
Discharged  277 65.2 
Left against medical advice  57 13.4 
Referred  5 1.2 
Died  86 20.2 
Discharge condition of survivors (N=339), n (%)   
Complete recovery  230 67.9 
Some improvement  78 23.0 
The same as admission  31 9.1 
GOS (N=425), n (%)   
1 86 20.2 
2 22 5.2 
3 9 2.1 
4 39 9.2 
5 269 63.3 
Neurologic sequelae (N=38*), n (%)   
Low GCS  18 47.4 
Neurologic deficit 11 28.9 
Seizure  9  23.7 
Cranial nerve palsy 2 5.3 
Length of hospital stay in days Mean  SD 
Total  8.9 6.4 
Discharged patients  11.0 6.6 
LAMA 6.1 3.7 
Referred  7.4 5.2 
Died  4.0 3.4 
*2 Patients had multiple complications 
GOS – Glasgow outcome scale, LAMA – left against medical advice 
Predictors of poor outcome –In hospital death – Admission Glasgow coma scale, presence of 
pneumonia and cranial nerve palsy during hospitalization, and treatment with dexamethasone 
were found to be independently associated with increased mortality. Accordingly, low GCS 
(impaired consciousness) was associated with poor outcome and improvement of GCS by 1 was 
associated with an increment of survival chance by 21% (AOR = 0.79; 95% CI = 0.73 – 0.85). 
Patients who had pneumonia at presentation were three times more likely to die in hospital than 
patients without pneumonia (AOR = 2.97; 95% CI= 1.38 – 6.41). Similarly, presence of cranial 
nerve deficits (III, VI and VII) at admission was associated with nearly 5 times increment of 
mortality (AOR = 4.73; 95% CI = 1.45 – 15.50). Adjunctive dexamethasone treatment was also 
associated with over 3 times increment of mortality (AOR = 3.38; 95% CI = 1.87 – 6.12) (Table 
4.5). 
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Glasgow outcome scale (GOS) was dichotomized into favorable (GOS = 5) and unfavorable 
(GOS =1 to 4) outcome. Low admission GCS (AOR = 0.77; 95% CI = 0.66 – 0.89) and 
dexamethasone treatment (AOR = 4.46; 95% CI 1.98 –10.08) were again found to be 
independently associated with unfavorable outcome at discharge.  
Fifty-two (12.2%) of patients were additionally treated with anti-tuberculous drugs with the 
presumptive diagnosis of tuberculous meningitis (TBM). These groups of patients had 
unfavourable outcome at discharge as compared to other groups (AOR = 2.78; 95% CI 1.06 – 
7.30). 
Neurologic sequelae – Focal neurologic deficits (AOR = 3.33; 95% CI 1.31 – 8.50), seizures 
(AOR = 2.20; 95% CI 1.03 – 4.67) and a low level of consciousness (AOR = 2.65; 95% 1.21 – 
5.81) at admission were associated with the occurrence of neurologic sequelae at discharge. The 
duration of illness before presentation was also associated with an increased occurrence of 
neurologic complications at discharge (AOR = 1.09; 95% CI 1.01 – 1.16). Accordingly, 
likelihood of this complication was found be increased by 9% for each day between onset of 
symptoms and presentation to the hospital.  
Table 4-5 – Factors independently associated with poor outcomes at leaving hospital in patients 
treated as bacterial meningitis at teaching hospitals in Ethiopia, 2011 – 2015. 
Variable  AOR 95.0% C.I. P-value 
Death  
Level of consciousness at presentation (for a 
point increase in GCS) 
0.79 0.73 – 0.85 <0.001 
Dexamethasone treatment 3.38 1.87 – 6.12 <0.001 
Aspiration pneumonia at presentation 2.97 1.36 – 6.41  0.006 
Cranial nerve palsy at presentation 4.73 1.45 – 15.50  0.010 
Low GOS  
Level of consciousness at presentation (for a 
point increase in GCS) 
0.77 0.66 – 0.89 <0.001 
Dexamethasone treatment 4.46 1.98 – 10.08 <0.001 
TB suspected cases 2.78 1.06 – 7.30 0.038 
Neurologic sequelae 
Focal neurologic deficit at presentation  3.33 1.31 – 8.50 0.012 
Seizure at presentation  2.20 1.03 – 4.67 0.041 
Duration of illness before presentation in days 1.09 1.01 – 1.16 0.020 
Impaired consciousness  2.65 1.21 – 5.81 0.015 
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As described above, 15% of patients left hospital against medical advice or referred for better 
care.  Separate analysis was done to assess if these patients differed clinically from discharged 
patients. Accordingly, they were found to have lower GOS, lower GCS and higher proportion of 
neurologic sequelae at leaving hospital (Table 4.6).   
Table 4-6 – Difference in secondary outcome variables between discharge patients and those 
who left the hospital against medical advice or referred to other centres in patients 
treated as bacterial meningitis at teaching hospitals in Ethiopia, 2011 – 2015. 
Discharge 
outcome 
GOS, N (%) Neurologic sequelae, N 
(%) 
Impaired GCS, N (%) 
2 3 4 5 P Yes No P Yes No P 
LAMA/ref
erred 
21 
(33.9) 
6 
(9.7) 
20 
(32.3) 
15 
(24.2) 
 
<0.001 
16 
(25.8) 
46 
(74.2) 
 
<0.001 
13 
(21.0) 
49 
(79.0) 
 
<0.001 
Discharge
d  
1 
(0.4) 
3 
(1.1) 
19 
(6.9) 
254 
(91.7) 
18 
(6.5) 
259 
(93.5) 
2 
(0.7) 
275 
(99.3) 
 
Dexamethasone treatment and its association with discharge outcomes – Chi-square test 
showed that dexamethasone was used more often in confirmed and probable cases of bacterial 
meningitis, those with turbid CSF and organism detected by Gram staining. On the other hand, it 
was found to be prescribed less often in HIV-positive patients as compared to non-HIV cases. 
There was also a clear difference in the pattern of dexamethasone treatment between hospitals 
ranging from 23.5% in Hawassa to 73.9% in Gondar. However, there was no difference with 
respect to presenting clinical conditions and prior antibiotic treatment (Table 4.7). 
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Table 4-7 – Comparison of background characteristics by dexamethasone treatment of patients 
treated as bacterial meningitis in Ethiopia, 2011 – 2015. 
Characteristics  Dexamethasone  No dexamethasone P value 
Mean age, year (SD) 30.1 (15.0) 33.9 (16.2) 0.116 
Duration of illness, days (SD) 5.2 (4.3) 5.0 (4.3) 0.683 
Diagnosis of meningitis     
Confirmed  12 (85.7) 2 (14.3)  
0.001* Probable  51 (62.2) 31 (37.8) 
Suspected  84 (42.9) 112 (57.1) 
Non-cases  67 (50.4) 66 (49.6) 
Prior antibiotic treatment     
0.096 Yes  45 (43.3) 59 (56.7) 
No  169 (52.6) 152 (47.4) 
Impairment of consciousness    
0.52 Yes  102 (52.0) 94 (48) 
No  112 (48.9) 117 (51.1) 
Focal neurologic deficit    
0.051 Yes  22 (66.7) 11 (33.3) 
No  192 (49.0) 200 (51.0) 
CSF appearance    
<0.001* Turbid  37 (64.9) 20 (35.1) 
Normal 68 (38.2) 110 (61.8) 
Detection of organism by Gram stain    
0.003* Yes  11 (84.6) 2 (15.4) 
No  89 ((43.0) 118 (57.0) 
HIV status    
0.048* Positive  7 (30.4) 16 (69.6) 
Negative 207 (51.6) 194 (48.4) 
Hospital     
 
<0.001 
Jimma  52 (42.6) 70 (57.4) 
Gondar  24 (26.1) 68 (73.9) 
Hawassa  65 (76.5) 20 (23.5) 
Arba Minch 73 (57.9) 53 (42.1) 
*statistically significant 
Dexamethasone treatment was associated with an increase of the in-hospital mortality, COR = 
3.18 (95% CI 1.90-5.33); p<0.001 and low GOS at discharge, COR = 2.65 (95%CI 1.76-3.99); P 
< 0.001. Multivariate logistic regression analysis also showed that dexamethasone treatment was 
independently associated with an increased in hospital mortality, AOR = 3.38 (95% CI 1.87-
6.12); P < 0.001 and unfavorable overall outcome, AOR = 4.46 (95%CI 1.98-10.08); P < 0.001. 
However, there was no association with neurologic sequelae at discharge (Figure 1).  
 
35 
 
 
Figure 4-5 – Effect of adjuvant dexamethasone treatment on discharge outcome in patients 
treated as bacterial meningitis in Ethiopia, 2011 – 2015. 
GOS – Glasgow Outcome Score 
As depicted on Table 4.5 above, dexamethasone was found to be one of the factors 
independently associated with poor outcome on multivariable analysis with best-fit model. When 
further analysis was done controlling for all potential confounders on multiple logistic 
regressions with forced entry, this association persisted. For instance, the odds of having low 
GOS at discharge was nearly 4 times, AOR=3.94 (95%CI 1.63-9.53; P=0.002) and its 
association with in hospital death was also nearly as much, AOR= 3.60 (1.97-6.60; P<0.001).  
Controlling for these individual variables also revealed similar finding as shown on Table 4.8.  
Dexamethasone and mortality – This association did not differ between older and younger 
patients, whether patient had delayed presentation or not, and whether patient took prior 
antibiotic or not. However, this association faded in HIV infected patients, those with neurologic 
deficit on presentation, those with abnormal CSF findings, and TB suspected cases.   
0%
10%
20%
30%
40%
50%
60%
70%
80%
Inhospital mortality Low GOS (1-4) at discharge Neurologic complications
No dexamethasone Treated with dexamethasone
Log. (No dexamethasone )
AOR = 3.38 (95% CI 1.87-6.12) 
P < 0.001* 
AOR = 4.46 (95% CI 1.98-10.08) 
P < 0.001* 
 
P = 0.456 
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Dexamethasone and low GOS – Age of the patient, presence or absence of HIV infection, and 
prior antibiotic treatment did not change the nature of this association. On the other hand, the 
association disappeared in TB suspected cases, those with confirmed BM and neurologic deficit 
on presentation. 
Table 4-8 – Relationship between dexamethasone and discharge outcome after controlling for 
potential confound variables 
 
Variables 
Death  Low GCS 
OR 95% CI P AOR 95% CI P 
Age       
< 50 years 3.08 1.74-5.48 <0.001* 2.83 1.79-4.48 <0.001* 
≥ 50 years 4.00 1.19-13.46 0.025* 2.68 1.0-7.21 0.051 
Duration of illness       
≤ 2 days 4.02 1.37-11.77 0.011* 2.05 0.94-4.50 0.072 
> 2days 2.93 1.62-5.30 <0.000* 2.91 1.79-4.72 <0.001* 
Level of conscious        
Conscious (GCS=15)  3.19 0.97-10.52 0.057 1.92 0.95-3.89 0.069 
Impaired (GCS=3-14) 3.04 1.65-5.61 <0.001* 3.17 1.81-5.57 <0.001* 
HIV status       
Positive  3.25 0.46-22.93 0.237 18.00 1.63-198.51 0.018* 
Negative  3.38 1.91-5.66 <0.001* 2.49 1.63-3.80 <0.001* 
Prior antibiotics       
Yes  3.59 1.24-10.38 0.018* 5.97 2.47-14.44 <0.001* 
No  3.04 1.68-5.50 <0.001* 2.07 1.30-3.29 0.002* 
Focal neurologic deficit       
Yes  3.20 0.67-15.38 0.146 0.80 0.16-3.99 0.789 
No  3.00 1.72-5.23 <0.001* 2.77 1.80-4.29 0.003* 
CSF appearance       
Turbid  2.72 0.67-11.11 0.163 2.44 0.79-7.51 0.121 
Clear   6.26 1.95-20.12 0.002* 4.28 2.14-8.58 <0.001* 
TB suspected        
Yes 3.90 0.45-34.02 0.218 3.46 0.83-14.36 0.087 
No  3.09 1.79-5.34 <0.001* 2.18 1.40-3.39 0.001* 
Diagnosis of meningitis        
Confirmed  - 1 1 - 1 1 
Probable  2.31 0.68-7.86 0.180 3.22 1.24-8.36 0.016* 
Suspected  3.38 1.73-6.59 <0.001* 2.09 1.16-3.75 0.014* 
Non-cases  6.98 1.50-32.56 0.013* 3.17 1.41-7.15 0.005* 
*statistically significant 
In summary, adjunctive dexamethasone treatment was associated with poor outcome in most of 
the groups except for patients whose diagnosis of bacterial meningitis is more likely as 
evidenced by turbid CSF and confirmed etiology, and in those suspected to have TBM. In these 
cases, dexamethasone therapy was not associated with any positive or negative discharge 
outcomes (Table 4.8).  
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One instance where dexamethasone with associated with positive outcome is decreased 
discharge neurologic sequelae in patients who had impaired consciousness at presentation, 
AOR=0.42 (95% CI 0.19-0.94; P=0.033). 
Key findings from retrospective study (summary) 
Total of 425 participants, 83.8% of which were younger than 50, were included in the study. 
Fever and headache were major presenting symptoms and half of them presented with 
impairment of mentation. Only 30% of patients presented within 2 days of symptom onset. A 
quarter of them took antibiotic therapy in the community for the same complaint before hospital 
presentation. The peak number of cases treated as BM at the hospitals correlates with lowest 
annual rain fall (November to January).  
Lumbar puncture for CSF collection was done in only 55.5% of patients and only 58% of them 
had complete biochemical and cytological analysis of the CSF. CSF abnormality compatible 
with BM was documented in only 96 patients and a pathogen was detected in 14 cases only.  
Eighty-six patients (20.2%) died before leaving hospital. Mortality was found to be high in those 
admitted with impaired consciousness, cranial nerve palsy and comorbid pneumonia. Adjunctive 
dexamethasone treatment was used in 50.4% of cases and was independently associated with 
increased in hospital death (AOR=3.38, 95%CI =1.87-6.12) and low GOS (AOR=4.46, 
95%CI=1.98-10.08). 
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4.2. Prospective study 
Study participants (Baseline characteristics) 
Total of 127 patients were included in this study. The mean age of the participants was 32.7 
years (SD=13.1) with range of 18 to 70; 108 (85%) were younger than 50. Men constituted for 
the majority, 79 (62.2%) of the participants. Seventy-seven (60.6%) of them were rural residents. 
Table 4-9 – Baseline demographic and clinical characteristics of patients treated as bacterial 
meningitis at Jimma University Specialized Hospital, Ethiopia 
Characteristics  Number  Percent  
Age (years)   
<50 108 85.0 
≥50 19 15.0 
Gender    
Male  79  62.2 
Female  48  37.8 
Residence    
Rural  77  60.6 
Urban  50  69.4 
Duration of illness in days, mean (SD) 5.6 (4.7)  
Presenting signs and symptoms    
Fever  116  91.3 
Headache  122  96.1 
Nuchal rigidity  106  84.1 
Vomiting  91  71.7 
Impaired consciousness 64  50.4 
Photophobia  52  41.3 
Seizure  28  22.0 
Neurologic weakness 9  7.1 
Hypotension  8  6.3 
Prior antibiotics  44 34.6 
Route of prior antibiotics    
Oral  17  38.6 
Parenteral (Intravenous or intramuscular) 27  61.4 
Reported prior meningococcal vaccine 7  5.5 
Known contact with patient of similar illness 3  2.4 
Comorbidities    
HIV 23 18.1 
Pneumonia  23 18.1 
Diabetes mellitus  4  3.1 
Current alcohol use 11 8.7 
Current smoker 9  7.1 
Others 8  6.3 
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The duration of illness before presentation was 5.6 days (SD=4.7) with range of 6 hours to 21 
days. About 80% (101) of patients presented within seven days of symptom onset, however, only 
37 (29.1%) of them presented within 2 days. Fever, headache and nuchal rigidity were the major 
clinical presentations reported in 116 (91.3%), 122 (96.1%) and 106 (84.1%) of the participants. 
Half (64) of them had impaired consciousness at presentation (Table 4.9).  
All patients were screened for HIV using rapid diagnostic test and the rate of HIV infection was 
found to be 18.1% (23 cases). Among the HIV patients, 20 have been diagnosed prior to current 
presentation. Twenty-three (18.1%) had concomitant pneumonia which was evidenced by 
physical examination and chest radiography. Eleven patients (8.7%) reported regular use of 
alcohol and 9 (7.1) were current smokers. Six of reproductive age women were pregnant. Seven 
patients reported taking meningococcal vaccine recently (Table 4.9). 
Six patients presented with petechial rashes. Figure 4.6 presents one of those patients with BM 
presenting with typical petechial rash along with other clinical characteristics. This is a 70 year 
old man presented with sudden onset of high grade fever and intense global headache followed 
by skin rash over his legs within one day. On examination, he had an overwhelming non-
blanching rash over his lower extremities which have become ecchymosed in some areas.  His 
CSF was frank pus on collection and revealed an extremely high white count (76, 500 cells/μL). 
Patient’s condition deteriorated fast despite high dose intravenous ceftriaxone. His blood 
pressure became unrecordable despite intravenous fluid administration. He finally died of septic 
shock with multisystem organ failure within 12 hours of hospital admission. 
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Figure 4-6 – Petechial rash of meningococcal meningitis with meningococcemia 
CSF characteristics  
Lumbar puncture to collect cerebrospinal fluid specimen was done in 109 (85.8%) of patients. In 
thirteen patients, LP was deferred due to contraindications (deep coma with GCS of ≤5 or focal 
neurologic deficit or cranial nerve palsy). In remaining 5 patients, the attempt to collect CSF 
specimen failed due to technical reasons. Of those who had CSF analysis, the specimen was 
collected after at least the first dose of antibiotics in 56 (51.4%) of patients; 21 (19.3%) had 
taken antibiotics for at least 24 hours (Table 4.10).  
In 57 (52.8%) them, purulent CSF was collected of which 52 were visibly turbid. The median 
white cell count was 115 cells/μL with range of 0 to 76, 500 cells/μL; 41 (37.6%) patients had 
≥1000 White cells/ μL. The case with highest white cell count is highlighted on Figure 4.6.The 
mean CSF protein was 114mg/dL (SD=97). Forty-seven (43.1%) had CSF to serum glucose ratio 
of <0.4. CSF analysis in 22 (20.2%) patients revealed normal protein concentration, glucose 
Clinical description of the patient 
70 years old man 
Presented on 25
th
 of July, 2015 
Duration of illness – 48 hours 
GCS = 12/15 
CSF findings: 
 Glucose ratio = 0.4 
 Protein = 198mg/dl 
 White cells = 76,500 cells/μL (PMN=72%) 
 CSF gram stain – negative  
 LAT – positive on N meningitidis ACY W135 
 Culture – N meningitidis 
CBC 
WBC =16,400 (PMN=73.6%) 
Hb = 14.9 g/dL 
Platelet =280,000/μL 
Outcome – died next day of septic shock with 
multisystem organ failure 
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level and white blood cell count (<5 cells/μL). Of these groups, 8 had microbiologically 
confirmed etiology (fungal and bacterial) and 14 had negative findings (Table 4.10).  
Table 4-10 – CSF profile of patients treated as bacterial meningitis at Jimma University 
Specialized Hospital, Ethiopia 
CSF profile  Number  Percent  
Lumbar puncture done  109 85.2 
Reason for not doing LP (N=18)   
Contraindication  13 72.2 
Technical difficulty (failed attempt, traumatic tap) 5 27.8 
Initial antibiotics before LP (of 109 tested) 56 51.4 
Gross appearance of CSF (N=109)   
Turbid  54 49.5 
Crystal clear 55 50.5 
CSF glucose ratio (N=89)   
<0.4 47 52.8 
≥0.4 42 47.2 
CSF protein (N=95)   
>100 39 41.1 
50-100 25 26.3 
<50 31 32.6 
CSF white cell (N=109)   
<100 47 43.1 
100-999 21 19.3 
≥1000 41 37.6 
Proportion of PMN in CSF (n=109)   
≥65% 53 48.6 
<65% 56 51.4 
Bacteria identified by (N=26)   
Gram stain 23 88.5 
LAT 15 57.7 
Culture  14 51.9 
At least two of them  15 57.7 
All of them 8 30.8 
Type of bacteria (N=26)   
Streptococcus pneumonia 13 50.0 
Neisseria meningitidis  9 34.6 
Haemophilus influenzae 3 11.5 
Escherichia coli 1 3.8 
CSF with no abnormal finding (of 109) 14 12.8 
Identification of etiologic agents – Among those who had CSF analysis, causative bacteria was 
detected in 26 (23.9%) patients. Streptococcus pneumoniae was identified in 13 (50%) of them; 
the other 9 (34.6%) were Neisseria meningitidis. One patient, with advanced HIV infection and 
strongyloides stercoralis hyperinfestation, had Escherichia coli meningitis. 
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Only 14 (51.9%) of those microbiologically confirmed cases were isolated on culture; 8 cases 
were identified on all the three microbiologic tests (gram stain microscopy, LAT and culture) 
(Table 4.10).  
Eleven of the cases with culture positive CSF did not receive any antibiotics before admission. 
Eight of the culture isolated organisms were Streptococcus pneumoniae cases. With regard to 
antibiotic susceptibility pattern, S. pneumoniae showed very high sensitivity for ceftriaxone and 
penicillin. All of the eight culture positive cases were susceptible to ceftriaxone whereas 7 were 
found to be responsive for penicillin. However, sensitivity of this organism against 
chloramphenicol, co-trimoxazole, ciprofloxacin and gentamycin was found to be low.  
Only three of the Neisseria meningitidis cases were isolated from culture. All were susceptible to 
penicillin but one case was found to be resistant against ceftriaxone.  
The Escherichia coli isolated in HIV patient showed extended betalactamase phenotype, being 
resistant against penicillin, amoxicillin/clavulanic acid and cephalosporin. It was found to be 
susceptible to gentamicin only. 
In five patients, fungal etiologies were isolated; four Cryptococcus neoformans and one Candida 
albicans. All of them were HIV patients. 
Other laboratory tests 
All patients had complete blood count, HIV test and blood film test for hemoparasite during their 
current admission. Leucocytosis (White count>11000/μL) was detected in 62 (48.8%) patients; 
54 (42.5%) had anemia as defined by WHO (13g/dL for men and <12g/dL for women), but only 
10 (7.9%) had severe forms (hemoglobin <8g/dL). The only acute phase reactant possible to do 
was erythrocyte sedimentation rate (ESR) which was found to be elevated in 78.6% of those who 
had the test; in 38.1% the elevation was significant (>50) (Table 4.11). 
Among HIV positive patients, 13 of the 16 who had CD4 count recently had <200 cells/μL 
(severe immune suppression). On WHO’s clinical staging, all of the HIV patients were at stage 3 
or 4. 
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The rate of co-infection with plasmodium species was very low with only two cases of 
Plasmodium vivax cases detected (Table 4.11). 
Table 4-11 – Other laboratory tests done for patients treated as bacterial meningitis at Jimma 
University Hospital, Ethiopia 
Tests done  Number  Percent   
Complete blood count 127 100 
Erythrocyte sedimentation rate (ESR) 84 66.1 
HIV test* 127 100 
CD4 count (for HIV patients only) 16 69.6 
Blood film for hemoparasite† 127 100 
Findings    
White cell count   
<4000 10 7.9 
4000-11000 (normal) 55 43.3 
>11000 62 48.8 
Hemoglobin    
Normal  73 57.5 
Anaemic (<13 for men, <12 for women) 54 42.5 
Platelet  (N=127)   
≥150,000/μL (normal) 109 85.8 
50000-149,000 13 10.2 
<50,000 5 3.9 
ESR (N=84)   
Normal (0-20) 18 21.4 
21-50 34 40.5 
>50 32 38.1 
CD4 count (N=26)   
<200 13 81.3 
200-349 2 12.5 
≥350 1 6.3 
Blood film for malaria (N=127)   
Positive 2
‡
 1.6 
*Test was considered as done in patients with already known HIV even though it was not 
done this time 
† Blood film was repeated at least twice in all of them 
‡ Both cases were Plasmodium vivax 
Clinical category of patients based on case definition 
Overall, 90 patients had fulfilled clinical and/or laboratory evidences compatible with bacterial 
meningitis. Fourteen cases even though they were treated empirically with antibiotics for 
bacterial meningitis had normal CSF findings; 23 had clinical evidence suggestive of other 
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diagnosis. Of the patients with compatible clinical and laboratory evidence for BM, 14 were 
additionally treated for other differential diagnosis (Figure 4.7).  
Apart from their CSF findings, patients with diagnosis other than bacterial meningitis had the 
following differences when compared to those with BM. Longer duration of symptoms (10.2±5.8 
versus 4.7±3.8 days, p<0.001); focal neurologic abnormalities (hemiparesis, P=0.019 and cranial 
nerve palsy, P=0.041) and were less likely to have fever at presentation (69.6% versus 96.2%, 
p=0.01). 
Twenty of patients treated for other diagnosis received treatment for tuberculous meningitis; 
however, its diagnosis was not confirmed. Five patients with confirmed fungal meningitis (see 
above) were treated with antifungal agents. Among 23 patients who fulfilled case definition for 
other differential diagnosis, treatment initiation for the differential diagnosis had a delay of 2.5 
days on average (SD=1.5).  
Ceftriaxone given as 2gm intravenously twice daily was the main stay of treatment; used as the 
only antibiotics in 91 patients and in combination with other antibiotics in 35 patients. Only in 
one patient was the combination of crystalline penicillin and chloramphenicol used. Forty-two 
(33.1%) of the patients were also given adjunctive dexamethasone treatment.  
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Cases treated as bacterial meningitis 
(N=127) 
Microbiologically proven 
bacterial meningitis 
(N=26) 
Bacterial meningitis with 
unidentified pathogen 
(N=38) 
Possible bacterial 
meningitis (N=26) 
Treated additionally for 
differential diagnosis (N=37)* 
  20 TB meningitis 
  5 Fungal meningitis 
  3 Intracranial bleeding (SAH) 
  9 Others (sepsis, malignancy,     
viral meningitis…) 
Non-cases (N=14)
‡
 
 CSF is normal in all of 
them and clinical findings 
were only mild 
 Bacterial meningitis less 
likely (N=37) 
13 S pneumoniae 
9 N meningitidis 
3 H influenzae 
1 E coli Other diagnosis 
likely (N=23)
‡
 
29 Deaths   8 
7 5 
9 
‡ Investigators’ diagnosis 
(based on predefined case 
definition) 
* Treat physicians’ decision 
TB - tuberculosis 
SAH –subarachnoid haemorrhage 
 
N=3 
N=5 
N=6 
Figure 4-7 – Clinical category of patients treated as bacterial meningitis based on predefined case definitions and their mortality at 
discharge, Jimma University Specialized Hospital, Ethiopia 
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Seasonal variability of cases 
The number of cases treated each year did not show uniform seasonal variability often 
described during outbreaks of meningococcal meningitis outbreak. However, the peaks for 
each year occurred during period of either January to March or October to December. On the 
other hand, the lowest number of cases recorded each year was during the rainy seasons of 
June to September.  However, except for 2014, there was paradoxical increase in number of 
cases in August (Figure 4.8). 
Apart from seasonal variability, there were also differences in number of cases treated as 
bacterial meningitis each year. The data was collected for 10 months in 2013. Despite this, 
the highest number of patients was seen that year with 50. This fell to 36 and 41 in 
subsequent years despite full 12 month months of data collection each. 
 
Figure 4-8 – Trends in the number of cases admitted to Jimma university hospital with 
bacterial meningitis between 1 March, 2013 to 31 December 2015 
Hospital course and discharge outcome 
Patients were followed daily with vital sign assessment and neurosign charts. Most patients 
had good response of their fever to antibiotic treatment. However, in 34 (28.1%) patients, the 
fever persisted beyond the second day of inpatient antibiotic treatment. Among patients who 
had impaired consciousness on presentation, 29 (45.3%) regained it within the first 3 days of 
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inpatient treatment. However, 24 (37.5%) of patients in this group did not regain their 
conscious till their death or discharge from the hospital. 
The average length of hospital stay was 13 days (SD=9) with range of 12 hours to 50 days. 
The mean duration of hospital stay in those who survived to discharge was 14.3 days 
(SD=8.7). Among deceased patients, the deaths occurred in the first 5 five days of admission 
in 15 (53.6%) of them. 
Multivariate linear regression models identified significant positive correlation between 
length of hospital stay (LOS) and the following variables: identification of bacterial etiology, 
HIV infection and presence of evidence for other differential diagnoses.  Accordingly, 
patients who had evidence of other differential/additional diagnosis stayed 5.8 days (1.98-
9.66) longer than those who did not (p=0.003). Similarly, HIV infected patients stayed 5 
more days (0.25-9.62) than those who were seronegative (P=0.039). On the other hand, 
patients with microbiologically proven meningitis had 5 additional days (0.74-9.94) in the 
hospital than the rest of the patients (p=0.024) (Table 4.12). 
Table 4-12 – Predictors of length of hospital stay in multiple linear regression with stepwise 
entry, controlled for age and sex 
 
 
Independent variables  
Regression 
Coefficients (B) 
Std. Error t P 95% CI for B 
Lower 
Bound 
Upper 
Bound 
Alternative Diagnosis 5.821 1.927 3.021 0.003 1.983 9.659 
Etiology identified 5.339 2.312 2.309 0.024 0.735 9.944 
HIV positive 4.934 2.352 2.097 0.039 0.248 9.619 
Outcome on leaving hospital – 76 (60%) patients were discharged with improvement, 9 left 
the hospital in the same condition, while 13 were discharged with some improvement but 
with apparent neurologic sequelae. Eighteen patients (14.2%) left the hospital against medical 
advice (self-discharged).The mortality rate in the hospital was 22.8% (29 deaths). Among 
survivors, 19 (19.4%) had unfavorable GOS (2-4).  
Headache and evidence of neurologic sequelae were the commonest symptoms at discharge. 
Among survivors, 18 (18.4%) had neurologic sequelae. Hemiparesis and coma were the 
commonest neurologic complication identified (Table 4.13).  
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MMSE was completed for only 72 of the survivors; its administration was limited by poor 
literacy status of these participants. Six (8.3%) of them had score of <24 at discharge from 
the hospital. 
Table 4-13 – Discharge clinical characteristics of patients treated as bacterial meningitis at 
Jimma University hospital 
Variables  Total, 
N=127 
 
Proven 
BM, 
N=26 
BM with 
unknown 
etiology, 
N=38 
Possible 
BM, N=26 
BM 
doubtful, 
N=37 
Status on leaving hospital N (%) N (%) N (%) N (%) N (%) 
Full recovery  76 (59.8) 14 (53.8) 23 (60.5) 18 (69.2) 21 (56.8) 
Some improvement 13 (10.2) 4 (15.4) 6 (15.8) 3 (11.5) 0 
The same condition 9 (7.1) 0 2 (5.3) 0 7 (19.9) 
Death  29 (22.8) 8 (30.8) 7 (18.4) 5 (19.2) 9 (24.3) 
Glasgow outcome scale      
Favorable (5) 79 (62.2) 13 (50) 26 (68.4) 18 (69.2) 22 (59.5) 
Unfavorable (1-4) 48 (37.8) 13 (50) 12 (31.6) 8 (30.8) 15 (40.5) 
Discharge symptom† (among 
survivors, N=98) 
     
Headache  18 (18.4) 3 4 5 6 
Fever  5 (5.1) 1 1 1 2 
Body weakness 
(hemiparesis) 
5 (5.1) 1 0 0 4 
Abnormal body movement 
(convulsion) 
4 (4.1) 1 0 1 2 
Uncommunicative  4 (4.1) 1 1 0 2 
Nuchal rigidity 4 (4.1) 1 1 1 1 
Hearing difficulty 3 (3.1) 2 1 0 0 
Blurring of vision 2 (2.0) 2 0 0 0 
Others‡  12 (12.2) 3 5 3 1 
Neurological sequelae (N=18) 18 (18.4) 5 2 1 10 
Hemiparesis  5 (27.8) 1 0 0 4 
Coma  5 (27.8) 1 1 0 3 
Seizure  4 (22.2) 1 0 1 2 
Decreased hearing (self-
reported) 
3 (16.7) 2 1 0 0 
Facial palsy 2 (11.1) 0 0 0 2 
MMSE (total evaluated = 72)      
≥24 66 (91.7) 11 20 16 19 
<24 6 (8.3) 1 2 0 3 
† Seven patients had two or more symptoms listed  
‡includes easy fatigability, poor appetite, feeling of unwellness 
MMSE – Mini-mental state examination 
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Table 4-14 – Univariate analysis of factors associated with unfavourable discharge outcome 
 
Variable  
Favorable 
outcome 
Unfavorable 
outcome 
OR (95%CI) P 
Age (Y), mean(SD) 32.2 (13) 33.6 (13.6)  0.564 
Gender       
0.957 Women  30 (62.5%) 18 (37.5%) Reference  
Men  49 (62.0%) 30 (38.0%) 1.02(0.49;0.2.14) 
HIV infection     
0.121 No 68 (65.4%) 36 (34.6%) Reference  
Yes 11 (47.8%) 12 (52.2%) 2.06(0.83;5.132) 
Pneumonia      
0.001* No 7 (30.4%) 16 (69.6%) Reference  
Yes 72 (69.2%) 32 (30.8%) 5.14(1.93;13.712) 
Time to antibiotics, h 101.6 168.3  <0.001* 
≤48hours 31 (77.5%) 9 (22.5%) Reference  
0.014* 
>48 hours 48 (55.2%) 39 (44.8%) 2.80 (1.19;6.57) 
Adjunctive dexamethasone      
<0.001* No  63 (74.1%) 22 (25.9%) Reference  
Yes  16 (38.1%) 26 (61.9%) 4.65 (2.11;10.25) 
GCS, score of 15 14 12  <0.001* 
>8 76 (66.1%) 36 (33.9%) Reference  0.006* 
≤8 3 (25%) 9 (75%) 5.85 (1.5;22.83) 
Hypotension  3 (37.5%) 5 (62.5%) 2.95 (0.67;12.93) 0.144 
Seizure  15 (53.6%) 13 (46.4%) 1.63 (0.70;3.82) 0.262 
Neurologic deficit  2 (22.2%) 7 (77.8%) 6.57 (1.31;33.1) 0.011* 
CSF appearance     
0.032* Clear  43 (78.2%) 12 (21.8%) Reference  
Turbid  32 (59.3%) 22 (40.7%) 2.46 (1.06;5.70) 
CSF glucose ratio (mean) 0.50 0.37   0.025* 
CSF protein, mg/dl (mean) 106.6  130.7   0.259 
CSF WBC, cells/μL (mean) 2113 3577  0.419 
Causative bacteria     
0.237 Others  8 (61.54%) 5 (38.46%) Reference  
Streptococcus pneumoniae 5 (38.46%) 8 (61.54%) 2.56 (0.53;12.43) 
Evidence supporting other diagnosis     
<0.001* No  67 (74.4%) 23 (25.6%) Reference  
Yes  12 (32.4%) 25 (67.6%) 6.07 (2.632;14.0) 
Fever persisting after 2 days     
<0.001* No  71 (81.6%) 16 (18.4%) Reference  
Yes  8 (23.5%) 26 (76.5%) 14.42 (5.52;37.68) 
*Statistically significant   
Factors associated with unfavorable outcomes 
In univariate logistic regression analysis, the following variables were found to be associated 
with unfavourable outcome: time to antibiotic treatment, presence of concomitant pneumonia, 
treatment with dexamethasone, low GCS on admission, neurologic deficit (hemiparesis or 
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cranial nerve deficit) on presentation, turbid CSF findings, low CSF glucose ratio, clinical 
clues supporting other diagnosis (TB meningitis, cryptococcal meningitis) and persistent 
fever after 2 days (Table 4.14).  
On multivariate analysis, the effect of most of these variables disappeared except for 
adjunctive dexamethasone treatment, persistent fever and HIV infection, the effect of which 
came into picture in multivariable analysis. However, the effect of these three variables is 
weak due to wide confidence interval (Table 4.15). 
Table 4-15 – Multivariate analysis of factors associated with unfavourable outcome 
(stepwise conditional logistic regression method). 
Variable  AOR 95.0% CI P 
Dexamethasone treatment 6.79 1.46-31.48 0.014 
Fever after 48hrs 25.0 5.55-112.59 <0.001 
HIV infection 17.87 3.23-98.78 0.001 
 
Key findings from prospective study (summary) 
Of the 127 participants, 85% were < 50 years of age. Fever, headache and nuchal rigidity 
were the major presenting symptoms. Half them also presented with impaired consciousness. 
Duration of illness before presentation was 5.6days (SD=4.7). The rate of HIV infection was 
18.1%. Twenty-three (18.1%) were diagnosed with comorbid pneumonia. 
CSF was analysed in 109 (85.8%) of patients however, only 90 (70.9%) of patients had 
evidences compatible with bacterial meningitis; only 26 of them had etiologic bacteria 
identified. S. Pneumoniae and N. meningitidis were the major causes. 
The in hospital mortality rate was 22.8% whereas, 18.4% of survivors had neurologic 
sequelae on discharge. HIV infection, fever persisting after 2 days of inpatient management 
and dexamethasone therapy were independently associated with increased mortality. 
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5. Discussion 
The findings in the two studies revealed that the care of patients with bacterial meningitis in 
tertiary hospitals in Ethiopia is hampered by multiple factors. In retrospective study, only 236 
(55.5%) patients had CSF analysis and a causative bacterium was identified in only 14 of 
them. Most, 109 (85.8%) patients in the prospective study had CSF analysis. However, 
etiologic agent for BM was identified in 26 (20.5%) patients only. In both studies, cases 
treated as BM in teaching hospitals in Ethiopia were found to have high mortality. Some of 
the major challenges identified were: (i) Patient with suspected bacterial meningitis did not 
receive proper diagnostic tests. (ii) The time from onset of illness to hospital presentation was 
found to be longer than most studies from high income settings. (iii) More than quarter of the 
patients have taken antibiotics in the community before hospital presentation. (iv) The rate of 
HIV infection was found to be very high as compared to community prevalence. Presence of 
HIV infection in patient with meningitis is associated with poor discharge outcome. (v) 
Dexamethasone treatment was associated with an increased mortality. 
Though there were significant differences in data quality based on the study designs, the 
findings from the prospective and retrospective studies were highly concordant. The classic 
triad of bacterial meningitis (fever, headache and neck stiffness) were present in more than 
80% of patients. The time from symptom onset to hospital presentation of 5 days on average 
is higher than most findings from other settings (2, 3, 38). In addition to this, there was high 
rate of antibiotic use in the community for similar complaint before presentation (24.5% in 
retrospective and 34.6% in prospective), a finding consistent with previous report from the 
country (48). The former is the likely cause for the delay of presentation. This might have 
resulted in patients presenting with poor clinical status: about half of the patients presented 
with impaired consciousness. Over 10% of patients presented with evidence of pulmonary 
aspiration with clinically evident pneumonitis. This probably reflects a prolonged period of 
loss of consciousness before presentation.  
The diagnosis of BM in the study settings was based mainly on clinical ground with no proof 
of the etiologies. The prospective design oversaw strict collection of CSF specimen (unless 
contraindicated or technically difficult) and its analysis, however, 44.5% of patients in the 
retrospective wing did not have CSF analysis. Moreover, 37 (29.1%) in prospective and 133 
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(31.3%) patients in retrospective group were given antibiotics despite the lack of evidence 
supporting the diagnosis of bacterial meningitis at all. Hence, patients included in the studies 
could have additional or alternative diagnoses other than BM. As a result, the reported 
morbidities, mortalities and disabilities may not directly relate to bacterial meningitis.  
The findings suggest that there is very low threshold to diagnose and treat bacterial 
meningitis in the setting despite lack of clear evidence for it. This may be due to the fact that 
BM is associated with high mortality and is fatal in most untreated cases (53). On the other 
hand, evidence-based guidelines are lacking for management of BM in resource poor settings 
(3, 16). These reasons might have led physicians to take pragmatic approach of empiric 
management of suspected cases without laboratory confirmation. However, such an approach 
may contribute to a poor outcome because the antibiotic sensitivity pattern is unknown and it 
can lead to the under-diagnosis or delay in treatment of other central nervous system (CNS) 
infections (16). 
Overall, the findings from this project can be seen from two major perspectives: (1) 
Strategies used for case management and (2) Treatment outcome of patients. Seasonality of 
the disease will also be discussed briefly. 
5.1. Case management strategies 
Assessment of management strategies for BM was the major focus of the retrospective study. 
It identified critical gaps at three levels in the management of bacterial meningitis in teaching 
hospitals in Ethiopia. (i) 44.5% of patients did not have lumbar puncture (ii) 42% of those 
who had their CSF specimen collected did not get proper analysis, and  (iii) 140 patients who 
had CSF analysis (among suspected unproven cases and non-cases) were treated as BM 
despite findings that did not support the diagnosis.  
However, about half of the patients presented with impaired consciousness and close to 10% 
had focal neurologic deficits both of which may be indicators of an increased intracranial 
pressure (54). Such patients should ideally have CT scanning before LP (11, 55), which is not 
widely available in the country and non-existent at all the hospitals during the study period. 
This may be a reason for the cautious approach by physicians in terms of undertaking LP. 
Additionally, lack of LP kits, shortage of supply for common CSF tests and skill gaps by 
53 
 
 
 
professionals (56) could also be the reason. Furthermore, many patients with non-suggestive 
(normal) CSF findings were still treated as BM. This may be due to treating physicians’ lack 
of confidence on laboratory results, an issue which needs further investigation. 
Empiric antibiotic choices for bacterial meningitis vary based on age, the setting and local 
antibiotic sensitivity pattern (11, 17). Combination of ceftriaxone and vancomycin is 
recommended in high income countries and in settings where penicillin resistance is common 
(12). However, data for antibiotic sensitivity in sub-Saharan Africa is scarce. Thus, antibiotic 
option is based on local availability and cost of the drugs (3, 57). WHO recommends 
ceftriaxone alone as treatment of choice in non-epidemic meningitis in Africa (57).  
On the other hand, standard treatment guideline by Drug Administration and Control 
Authority of Ethiopia (recently renamed as Ethiopian Food, Medicine and Health Care 
Administration and Control Authority) recommends ceftriaxone and vancomycin as first 
choice, adopting the recommendation from high income countries. It also recommends 
penicillin and chloramphenicol as second options (58). However, there is no large scale 
published national data on local antibiotic sensitivity pattern and cost-effectiveness to support 
this recommendation. Recent small scale studies in the country revealed that S. pneumonia is 
highly sensitive to ceftriaxone (59) and penicillin (47, 59, 60). Similar susceptibility pattern 
for S. pneumonia was found in the current study.   
For individuals older than 50 years and those with immune suppression, empiric treatment 
should include antibiotics against Listeria monocytogenes (8, 11). Similarly, the Ethiopian 
standard treatment guideline for general hospitals (58) and guidelines in developed countries 
(12) recommend ampicillin in such patients. Even though there is a tendency to use it more in 
older patients in this study, it was not universally administered in patients with the indication. 
For instance, only 26.1% of patients older than 50 years and 4.3% of HIV patients were given 
ampicillin.  
Adjuvant corticosteroid in management of bacterial meningitis in high income countries is 
now part of standards of care in BM (61, 62). However, its benefit in low and middle income 
countries has become highly contentious and its routine use in such settings has never been 
supported with strong evidence (38, 63, 64). Despite this, national standard treatment 
guidelines of some countries in sub-Saharan Africa have kept recommending its routine use 
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(58, 65), an adoption of recommendation for high income countries (61, 62). The finding in 
our study, where dexamethasone was used in half of the patients, is a testimony of scepticism 
towards the current recommendation in low income countries. However, its uncontrolled use 
in settings with high HIV prevalence and those with potential alternative diagnosis may be 
deleterious. 
In general, the finding from all the hospitals in this study does not strictly conform to one 
recommendation. This shows lack of local evidence-based case management strategies and 
absence of consensus among clinicians and hospitals. It also reflects a decline in use of 
penicillin and chloramphenicol in the management of BM in the country. 
In addition to empiric treatment for BM, physicians at each hospital have also tried to address 
common differential diagnosis including cerebral malaria, tuberculous meningitis and viral 
meningitis. Even though the effort and responsiveness of treating physicians to the situation 
at stake should be commended, care should be made to avoid unnecessary use of 
antimicrobial agents. Such empiric therapy may also delay management of other potential 
disorders of the central nervous system.  
The challenges in diagnosis and treatment of serious infectious diseases in the country may 
not be limited to bacterial meningitis and teaching hospitals. Even though this study was 
limited to such hospitals, the situation in primary hospitals in the country may not be different 
or even worse. This may result in a serious consequence on overall health care system in the 
country. First of all, over/unnecessary antibiotic prescription may contribute to the ever 
increasing antimicrobial resistance. Secondly, it may result in overutilization of the limited 
resource in terms of unnecessary admission and intravenous antibiotic use.  
5.2. Treatment outcome  
The overall outcome assessment on leaving hospital revealed that 156 (36.7%) in the 
retrospective study and 48 (37.8%) in the prospective study had unfavorable outcome (GOS 
1-4). The in hospital mortality rates of 22.8 % in prospective and 20.2% in retrospective are 
comparable with findings from high income countries; 21% in the Netherlands (2), 21% in 
Sweden (66) and 26% in USA (33). When compared to findings from low income countries, 
Malawi for instance with in hospital mortality of over 40% (7, 20), the findings in these 
studies is much lower than expected in the setting. However, the findings in the current 
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studies may not reflect the real mortality associated with BM in the country. This is because 
the diagnosis of BM in several of the patients was unclear and it is likely that many of these 
patients suffered from diagnosis other than BM.  
Furthermore, it should also be noted that a relatively low prevalence of HIV in our study 
(5.4% and 18.1%) makes a comparison with Malawi study difficult because of high 
prevalence (>90%) in that study.  
The documented short-term neurologic sequela in survivors was 18.4% (prospective) and 
11.2% (retrospective), lower than in most reports on the outcome of BM (2, 7, 20, 33, 35, 
66). As there is no trend of routine neurologic evaluation at and after discharge of patients 
with meningitis, only severe and symptomatic forms were included here. These findings did 
not include subtle sensory neural hearing loss which was difficult to assess.  
In addition to this, due to the fact that significant proportion of patients in these studies had 
potential alternative diagnosis, the reported finding may not reflect the true problem. The 
difference in findings between the prospective and the retrospective is a proof for this and 
may be due to the difference in quality of data and characteristics of the participants.  In 
complement with this, subgroup analysis in retrospective study based on case definition 
revealed higher rate of neurologic sequelae (15.6%) in those with CSF evidence for bacterial 
meningitis (possible and confirmed cases) versus 7.0% in the others. These all reflect that the 
overall neurologic sequelae in patients with bacterial meningitis in the setting would be much 
higher than reported here had there been standard evaluations for their presence. 
Because of the design problem and poor documentation in the setting, a common problem for 
the retrospective study, the morbidities reported could also be an underestimate in true BM. 
Moreover, significant proportions of the patients left the hospital against medical advice or 
were referred to other centres for better care. Most patients in these groups had a poor clinical 
status at leaving the hospital as compared to the other groups (Table 4.13). This could have 
also resulted in underreporting of the true mortality and complications related to the cases. 
With exception to adjunctive dexamethasone treatment (see below), the factors associated 
with poor outcome are in line with most of the studies from low income and high income 
countries (2, 7, 9, 20, 33, 64, 66). Impaired levels of consciousness along with longer 
duration of symptoms before hospital presentation were main reasons for occurrence of 
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aspiration pneumonia. Their presence altogether contributed highly for unfavorable outcome 
(2, 27).  
The effect of HIV infection on outcome came to picture in prospective study only which 
showed an independent association with unfavorable outcome albeit wide confidence 
interval. This effect could have been underpowered due to small sample size. Nevertheless, 
the effect of advanced HIV infection on outcome of serious bacterial infections like BM is 
not an overstatement even though evidence from well-designed studies is limited (36). 
Moreover, the rate of HIV infection of nearly 20 times that of the community prevalence 
[18.1% versus 1.14% (67)] reflects a significant interaction. Large scale prospective studies 
from settings with high prevalence of both conditions are needed to uncover their overlaps, 
effect on outcome and best treatments in such conditions.  
However, conventional poor prognostic indicators like etiologic bacteria and age of patients 
were not found to be associated with adverse outcome. The study was not able to detect an 
effect of these factors due to small number of confirmed cases and due to the fact that only 
outcome at leaving hospital was assessed. Furthermore, about 85% of patients were younger 
than 50 years; fewer cases in the other group might have underpowered the effect of age on 
outcome.  
As described above, the etiologic diagnosis for bacterial meningitis and other differential 
diagnosis were not possible for majority of patients. This has resulted in mis-diagnosis of 
other etiologies and hence a delay of their treatment. Patients who fell in this category of 
diagnosis were found to have unfavorable outcome at discharge. This effect can be due to one 
or more of the following reasons. First of all, these patients had longer duration of the illness 
before admission and the treatment for possible diagnosis was started after two days of 
admission. They also had higher rate of focal neurologic deficit at presentation and treatment 
with antibiotics in the community. It is more likely that these patients had alternative 
diagnoses other than bacterial meningitis and tuberculosis, due to the epidemiology, tops the 
list. It is thus possible that delay of treatment for the tuberculosis or other alternative 
diagnoses might have contributed to poorer outcome at discharge. 
Adjuvant corticosteroid in management of bacterial meningitis in low and middle income 
countries, and in settings with high HIV prevalence in particular, has never been proven 
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beneficial (38, 63, 64). To date, there is no recommendation of its use in such settings. 
However, physicians in settings with little evidence and diagnostic facilities like Ethiopia 
have continued its use based on recommendation for high income countries (11). The finding 
in our study, where dexamethasone was used in half of the patients, is a testimony of 
scepticism towards the current recommendation in low income countries.  
This study revealed that there is no any positive outcome associated with dexamethasone 
treatment in BM. It was rather associated with higher mortality and lower discharge GOS 
which persisted despite thorough subgroup analysis. Even though lack of evidence for its 
benefit is consistent with previous findings from similar settings (38, 63, 64) no simple 
explanation can be given for the negative effects. As it has repeatedly been highlighted in this 
paper, majority of the cases included in this study did not have confirmed diagnosis of 
bacterial meningitis. Hence, it is possible that some of the patients could have other 
alternative diagnoses. Dexamethasone administration in such conditions and other potential 
brain insults without treating underlying disease condition could have resulted in poorer 
outcomes. As this is the first study that looked at the effect of dexamethasone in patients 
treated with presumptive diagnosis of BM, it makes it valuable for the real situation in 
developing countries.  
5.3. Seasonal variability 
Bacterial meningitis, meningococcal meningitis in particular, is known for its notorious 
seasonal variability related to the amount of rain fall (25, 60, 68). Nevertheless, seasonal 
variability has also been documented in pneumococcal meningitis (20, 69). This seasonal 
variability in tropical settings is said to be due to more of environmental factor than the 
etiologic agent (60, 70, 71). Understanding seasonality of meningitis in the area is important 
for public health intervention (25, 68). 
Though there was no uniform pattern in seasonal variability of number of cases in the current 
studies, the peak number of cases in the dry months and the nadir in the rainy season reflect 
some patterns consistent with the findings described above (25, 70). Thus, the epidemiologic 
and environment explanations of these variations cannot be denied. However, the seasonality 
in these two studies can have more explanation in the study settings. Besides real seasonal 
variability of the disease, socio-economic factors and infrastructure problems may explain the 
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differences. Over 60% of the patients were rural residents and farmers. As river volumes 
increase during rainy months of June to September, roads may be difficult to access hospitals 
during this time. Moreover, due to subsistent livelihood of these farmers, visiting hospital far 
from harvest season may be financially difficult. 
In addition to these factors, the lost documentation/charts during 2011 and 2012 in 
retrospective study might have also resulted in lower number of cases during these times. In 
the prospective study, design effect of the research has likely affected the number of cases 
since establishment of microbiology late 2013. Number of cases treated as bacterial 
meningitis since then was less than before but more cases had suggestive CSF findings as 
compared to previous years. 
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6. Conclusion and recommendation 
These studies indicate that time from onset of illness to hospital presentation is longer than 
findings in most literatures. Moreover, a significant proportion of patients have been treated 
with antibiotics for the same problem before hospital presentation. As a result, most patients 
presented with poor clinical status as evidenced by low GCS and aspiration pneumonitis.  
Most patients who were treated for suspected BM did not receive a proper diagnostic workup 
and were treated only based on clinical suspicion. Besides, the antibiotic choice was not 
tailored to specific situation and clinical condition of the patient. Moreover, diagnostic and 
therapeutic practices were found to markedly vary between the hospitals and clinicians. 
The rate of HIV infection was found to be much higher than the expected community level 
prevalence. Most patients with the infection had very low CD4 counts and advanced stage 
disease on clinical assessment. Its presence was also associated with unfavorable discharge 
outcome.  
Dexamethasone, despite lack of its benefit in such settings, was commonly used as adjunctive 
treatment. Its use in management of suspected cases of bacterial meningitis was associated 
with an increased mortality and poor discharge GOS. This finding re-affirms the lack of its 
benefit and shows that there are potential deleterious effects in low income countries and in 
unconfirmed cases.  
Thus, it is highly recommended that standard treatment guidelines should be extracted from 
local data and case management should be based on available and cost-effective diagnostic 
and therapeutic strategies. Large scale nationwide prospective study is mandatory to achieve 
this goal. To date, there is no evidence supporting the benefit of dexamethasone in suspected 
or confirmed cases of bacterial meningitis in low income settings. Therefore, physicians 
should abide by the current recommendation and refrain from its overzealous use in such 
settings.  
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7. Limitations  
Prospective study – This is a study from single teaching hospital with relatively better setting 
and trained professions for the country. As a result, the reported outcome may not be 
representative for nation. Secondly, the outcomes reported included only discharge conditions 
and overt neurologic sequelae. Thus, the real mortality related to the problem may be more 
than stated here. Moreover, the small number of confirmed cases might have underpowered 
the effect of common outcome predictors. 
The interruptions and absence of some of the supplies from national marker have resulted in 
occasional interruption of microbiology services. The fact that there was no CT scan service 
at the hospital and that full laboratory services were limited to working hours only were other 
setbacks. 
Retrospective study – Poor documentation and lost medical records were limitation during the 
study. Patients included in the study were not confirmed cases of bacterial meningitis and 
hence its true outcome could not be addressed in this study. Furthermore, because only 
teaching hospitals were included in the study, the findings may lack national 
representativeness and may not reflect the real practice throughout the country. On the other 
hand, as it is common situation to have interruption of certain diagnostic laboratories and 
drug supplies in the settings, the diagnostics and therapeutic agents used may be affected by 
these factors and may not reflect management approach employed by the hospitals and/or 
practitioners at all times. Nevertheless, it must be assumed that the rate of treatment of cases 
with suspected BM lacking any diagnostic workup is even higher throughout the country. 
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8. Challenges 
Apart from very few studies presented in the introductory part of this thesis, information 
regarding morbidity, mortality and case management of BM in the country was few and far 
between. When the proposal for this project was written, no formal data could be traced 
regarding bacterial meningitis, and even more broadly, for CNS infections in general at 
Jimma University Hospital. There was no microbiology unit, no treatment guideline and even 
no registration for number of cases treated annually with bacterial meningitis. Thus, 
everything had to start from the scratch. The annual number of cases could only be reviewed 
from admission registration book which revealed about 90 to 120 admissions due to ‘bacterial 
meningitis’ 
The initial design of this project was solely prospective with the aim of assessing the impact 
of HIV infection on outcome of bacterial meningitis in Ethiopia. The project started with the 
expectation of 100 cases of bacterial meningitis annually as it was found on admission 
registration book revision during proposal development. The target sample size for this 
design was 186 confirmed cases of bacterial meningitis (138 HIV negative and 46 HIV 
positive). However, assessing the data collected in the initial 12 months of data collection 
revealed that most patients treated as bacterial meningitis were not actually confirmed cases. 
It was also found that most patients treated as BM at the hospital were not having the disease. 
As a result, the planned sample was predictably unachievable with this design during the PhD 
period.  Although this finding was not what was initially intended, it revealed a major gap in 
the management of BM at the hospital.  
To supplement this finding, a separate retrospective wing was added to the project with the 
aim of assessing these gaps of patient care in four teaching hospitals in Ethiopia.   
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Subsequent plan 
1. Make short communication with responsible organizations under federal ministry of 
health Ethiopia (Food, Medicine and Health care Admiration and Control Authority 
[FMHACA], Ethiopian Public Health Institute [EPHI]) 
2. Prepare local guideline with expertise in the field 
3. Molecular analysis of over 500 CSF in the storage to investigate bacterial, viral or fungal 
causes of meningitis 
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Annex – 2 Case reporting format for Prospective study
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Annex – 3 Collection, processing, analysis and interpretation of CSF 
specimen 
Collection of CSF – All patients suspected of having bacterial meningitis were screened for 
contradiction of lumbar puncture (LP).  LP was differed in patient with any of the following 
conditions. 
 Evidences of increased intracranial pressure (diplopia, abnormal pupillary responses, 
unilateral or bilateral motor posturing or papilledema) 
 Focal neurological signs or seizures 
 Local infection (in the area where LP would be performed) 
 Severe thrombocytopenia (<20 × 109/L) 
 Cardio-pulmonary compromise  
 Spinal deformity 
 Lack of patient cooperation 
As there was no CT scan facility at the hospital, the decision to do LP in patients in coma was 
left to the treating physician. However, due increased risk of herniation, LP was differed in 
patients with GCS of less than 5/15.  
Lumbar puncture was done under possible aseptic condition for all patients with suspected 
BM to collect CSF specimen. This was done as soon as it was possible (before antibiotics 
administration). However, if the LP was not possible within an hour of presentation or 
consideration of diagnosis of BM, patient was given first dose of antibiotics and CSF 
collection was done within 24 hours of this. About 2-3 ml of CSF specimen was collected in 
two separate sterile tubes each.  In case the tap was traumatic, the specimen was collected 
serially until the fluid became clear. The tubes were labelled as ‘1’ and ‘2’ based on their 
collection. The specimen was then sent to microbiology unit within 30 minutes of collection 
with special request form that contains demographic data, brief clinical description and 
whether patient has taken any prior antibiotics or not. 
Processing of sample – Macroscopic appearance of CSF was observed and documented as 
crystal clear, turbid or bloody/traumatic.  
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The specimen from first tube was used for quantification of CSF glucose and protein levels. 
The second tube was used for cell count and microbiologic analysis. The specimen was 
centrifuged at 1500-3000 ×g for 20 minutes and the sediment was used to inoculate to culture 
media and for direct smear examination of gram-stain specimen. The supernatant was used 
for bacterial antigen detection.  
Culture – The sediment of the centrifuged CSF was inoculated on to three plates as follows: 
1. Blood agar plate (with Columbia 5% Sheep blood) incubated at 37°C in 5-10% 
CO2 
2. Chocolate agar plate incubated at 37°C in 5-10% CO2 
3. MacConkey agar incubated at 37°C 
Inoculated primary plates were incubated for 72 hours. The plates were visually inspected 
daily for any growth for three days. 
Gram-stain and microscopic evaluation – The CSF specimen was stained with gram-stain 
within 2 hours of its collection and from culture specimen if there was any growth to identify 
bacterial etiologies. 
Interpretations of growth and gram-stain – Presumptive identification of three major causes 
of meningitis (N. meningitidis, S. pneumoniae, and H. influenzae) was made on the basis of 
growth and colony morphology on blood agar plate and chocolate agar plate, and a Gram 
stain of the organisms.  
Blood 
agar 
Chocolate ager Morphology (microscopic finding) Interpretation 
+ + Gram-positive diplococci in short chains S. pneumoniae 
+ + Gram-negative diplococci N. meningitidis 
- + Pleomorphic gram-negative rods 
(coccobacilli) with random 
arrangements 
H. influenzae 
In case of growth on MacConkey agar; biochemical test for urease, indole, citrate, lysine, 
hydrogen sulphide and gas production was done to different the type of bacteria. 
Antimicrobial susceptibility tests– all growths were tested for antibiotic susceptibility pattern 
using antibiotic discs that represented common antibiotics used in the setting. These included 
penicillin G, ampicillin, amoxicillin/clavulanic acid, ceftriaxone, gentamycin, 
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chloramphenicol, co-trimoxazole and ciprofloxacin. The result was interpreted as sensitive, 
intermediate and resistant according to the size of zone of inhibition which was interpreted 
based on European Committee on Antimicrobial Susceptibility Testing (EUCAST) 
Breakpoint tables for interpretation of MICs and zone diameters Version 4.0. It can found at: 
http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/Breakpoi
nt_table_v_4.0.pdf  
Latex agglutination test (LAT) – CSF samples were tested for bacterial antigen detection by 
using the bacterial antigen kit (Wellcogen® Bacterial antigen kit, UK). It is a latex 
agglutination test to detect antigens of 5 groups of organisms: 
1. Group B streptococcus (GBS)  
2. Haemophillus influenzae type B (Hib)  
3. Streptococcus pneumoniae  
4. Neisseria meningitidis ACY W135  
5. Neisseria meningitidis B/Escherichia coli K1 
Other tests from CSF – Acid-fast bacilli staining and microscopic evaluation of the specimen 
was done for most of the patients. In all HIV patients, Indian ink staining of the specimen 
was done and the specimen was inoculated into Sabouraud dextrose agar for detection of 
fungal meningitis. 
Reporting of the result – The report of laboratory findings was documented on a report form 
specifically prepared for this study. This is located on the second page of the request form. 
CSF storage for future analysis – About 2ml of specimen from the second tube was 
immediately stored in -20
0
C freezer after doing all the above tests. It was later transferred to -
80
0
C for possible further molecular analysis in the future. 
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